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resumo 
 
 
Nos últimos anos, a administração transdérmica de fármacos foi aponte como 
uma via de libertação de fármacos de sucesso devido às suas enumeras 
vantagens. Relativamente aos sistemas convencionais, este é um sistema não 
doloroso, apresenta menos efeitos secundários e possibilita uma dose menos 
frequente. Os pensos representam a maior quota do mercado de sistemas de 
libertação transdérmica de fármaco. No entanto, a sua aplicação tem sido 
restringida pelos atuais problemas associados à sua administração passiva. 
Com base no conceito de biomimetismo, um novo e otimizado sistema para 
administração transdérmica de fármacos é aqui proposto, bioinspirado na 
capacidade das abelhas aprisionarem e, consequentemente, libertarem o pólen 
durante o processo de polinização. Assim, foi desenhado um penso hierárico 
biomimético obtido a partir de polidimetilsiloxano (PDMS) com um micropadrão 
de pilares (imitando o pêlo presente nas patas das abelhas). A otimização do 
sistema foi obtida pela conjugação de micropilares espaçados com a mesma 
distância que o diâmetro das partículas de fármaco. Obteve-se assim uma 
eficiência de aprisionamento de 24,8 ± 0,4 mg/cm2, estando acima dos valores 
obtidos para os pensos atualmente disponíveis no mercado, bem como na 
maioria dos trabalhos até aqui efetuados. A tetraciclina, um antibiótico modelo, 
foi aqui utilizado para determinar o perfil de libertação de dois sistemas 
diferentes: pensos com tetraciclina em pó ou com micropartículas de alginato 
encapsuladas com esse mesmo fármaco. Enquanto o pó de tetraciclina foi 
rapidamente libertado, o sistema mais complexo permitiu uma libertação 
controlada do composto ativo durante 5 dias. Os pensos foram caracterizados 
por microscopia eletrónica de varrimento, microscopia de fluorescência e 
resistência à tração. Além disso, a atividade antimicrobiana também foi também 
verificada. Em suma, os resultados obtidos propõem a aplicação deste penso a 
nível clínico, proporcionando uma elevada concentração de fármaco que poderá 
resolver os problemas atuais associados aos sistemas de administração passiva 
de fármacos. 
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abstract 
 
In the last years, transdermal drug delivery has been exploited as a successful 
controlled drug release route due their several advantages (e.g. no painful, less 
frequent dosage and side effects), being the patches the largest market share of 
such systems. Nevertheless, current problems associated with passive delivery 
patches have been limiting their application. Based on the insights behind the 
biomimetics concept, herein we propose as novel and optimized system for 
transdermal drug delivery purposes, a bioinspired patch based on the 
remarkable bee’s ability to catch and release the pollen during pollination. For 
this purpose, a hierarchical biomimetic polydimethylsiloxane (PDMS) 
micropatterning patch with micropillars (mimicking the hair of bee’s legs) was 
engineered. An optimized system was obtained through the combination of patch 
with micropillars spaced with the same distance as drug microparticles' diameter. 
In fact, an entrapment efficiency of 24.8 ± 0.4 mg/cm2 was achieved, being above 
the actual commercially available patches and most of the current research 
works. The release profile was determinate to two different systems: patches 
with either tetracycline hydrochloride powder or tetracycline loaded alginate 
microparticles, a model antibiotic. While tetracycline powder was immediately 
release, the most complex system allowed for a controlled and sustained release 
of the active pharmaceutical ingredient (API) for 5 days. The engineered patches 
were characterized by SEM, fluorescent microscopy, tensile strength and 
antimicrobial activity was also verified. The results herein obtained suggest that 
the optimized patch could be further developed for clinical applications, providing 
high drug concentration that could solve the current problems associated with 
passive drug delivery patches. 
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Chapter 1- Motivation 
Wound healing is a well-studied process that consists in the repair of a tissue after 
trauma. One of the most affected tissue is skin, where epidermis and dermis develop a 
protective barrier that once broken, initiates a cascade of cellular and chemical signals that 
will promote the damage repair.[1] Wound healing is a complex set of reactions and 
interactions with cells and “mediators” which is normally divided in three steps: 
inflammatory, proliferative and remodelling phase (Figure 1.1). Haemostasis is the initial 
step and allows the foundation of the healing process. On the other hand, the inflammatory 
phase is characterized by vasodilation and the increase the vascular permeability and is 
marked by platelet accumulation, coagulation, and leukocyte migration. The proliferative 
phase is distinguished by re-epithelialization, angiogenesis, fibroplasia, and wound 
contraction. The final step is the remodelling phase that takes place over a period of months, 
during which the dermis responds to injury with the production of collagen and matrix 
proteins and then returns to its preinjury phenotype.[2] 
 
Many factors can lead to impaired wound leading. This will affect wound 
characteristics and healing capacity. The main local factors are the wound oxygenation and 
infection. Oxygen is a critical parameter in the healing process preventing wounds from 
infections, enhancing collagen synthesis and allowing wounds contraction. The critical point 
of healing is the infection. When skin is injured an inflammatory response is developed due 
to presence of microorganisms at skin surface that have access to the underlying tissues. 
Inflammation is a normal step of wound healing and is responsible for the removal of such 
microorganisms. When the normal microflora of skin is not restored, inflammation may be 
prolonged and the wound may enter a chronic state and fail to heal. The impaired wound 
Figure 1.1. Wound healing process- inflammation, proliferation and remodelling. 
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healing and the associated inflammatory response are related with age, stress, obesity, sexual 
hormones, nutrition, medication, diseases like diabetes or alcohol consumption. 
After many years of R&D, drug delivery systems (DDS) were appointed as the most 
effective strategy, improving the pharmacological and therapeutic properties of drug. These 
systems not only facilitate the handling and administration of drugs and regulate the local or 
systemic release, but also aid the drug to overcome certain barriers and fit the release process 
to specific therapeutic demands.[3] Skin allows a large and readily accessible surface area for 
the application and absorption of a patch-like device to its surface, i.e., a non-invasive 
procedure that will promote a continuous intervention.[4] In the last years, transdermal drug 
delivery has been exploited as a successful controlled drug release platform that has received 
regulatory approval. In fact, there are already a set of products with this concept present in 
the market.[5] Transdermal DDS must be applied when a drug has a significant first-pass 
effect in the liver, being prematurely metabolized in the pre-systemic stage. Hence, 
transdermal drug delivery allows for less frequent dosing or steady delivery profiles and is 
also a suitable alternative to hypodermic injection, which is painful and makes use of large 
amounts of dangerous medical devices, increasing the risk of disease transmission (e.g 
through needles re-use).[6,7] 
A large set of distinct transdermal DDS have been developed with different designs, 
polymeric arrangements and drug particles embedded. Designs with different degrees of 
development were produced from the humblest system, based on passive drug delivery with 
little/no permeation enhancement, to the most complex transdermal DDS that enable the 
delivery of small molecules and macromolecules.[8] The use of these patches with different 
designs will mostly depend on drug properties (e.g. molecular weight and physicochemical), 
as well as the required amount to accomplish an effective treatment.[6] Based on the 
extraordinary potential behind the DDS, drug carriers (either at nano- or micro-scale) can be 
incorporated in patches in order to improve drug pharmacological properties, prompting a 
more efficient treatment.[3]  
The concept of bio-inspired, bioengineered and biomimetic drug delivery carriers is 
emerging nowadays, aiming to understand how nature designs, processes and molecular 
building blocks enable the fabrication of high performance soft materials and polymer 
composites. These designs allow the engineer of new molecules and materials with novel 
properties. In fact, a better understanding of biological systems in conjunction with the 
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advanced biotechnology tools allows the re-engineering of various at micro and nono-scales 
natural systems enabling their multiple application in the delivery of molecules such as 
proteins and small interfering RNA, and others therapeutic agents.[9]  
Many soft biomimetic synthetic adhesives have also been studied in order to support 
macroscopic masses, normally inspired by animals and insects. Nevertheless, bioinspired 
adhesion that is tuned to micro- and nano-scale sizes and forces is poorly exploited. 
However, such adhesive forces are critical in the adhesion of micro and nanoparticles to 
surfaces, which are relevant to a wide range of industrial and biological processes such as 
drug delivery. Honey bees for instance, can carry large amount of pollen in their legs and 
body, mostly in the space between hair legs. Bees have a typical branched hair with 
numerous short lateral barbs and pollen grains are caught and held between the barbs of 
adjacent hair. The hair covering the body allows the temporary retention of pollen, which is 
then removed by the combing action of the legs' brushes. Together, pollens and bees' hair 
legs, whose adhesion is critical to plant pollination, are an optimized system that can be used 
to inspire the develop of a hierarchal system based on the adhesion between particles and 
micro-patterned soft matter surfaces.[9,10]  
Microfabrication allows the production of micro- or nano-structures. In most of the 
cases the process is based on a variety of patterning-techniques, such as photolithography, 
that enables the mass production of patterned structures. Nowadays, soft lithography is 
commonly used in microfabrication and represents a non-photolithographic strategy based 
on self-assembly and replica moulding for carrying out micro- and nanofabrication. This 
technique is low in capital cost, easy to learn, straightforward to apply and accessible to a 
wide range of users and can be apply to a wide variety of materials and surface chemistries. 
Microfabrication technology has been applied in drug delivery systems fabrication with 
different materials. This approach can be applied to develop biomimetic systems such as 
membranes with a micropatterning surface. According to the principles behind the 
biomimetics, effective drug carries can be developed based on a natural system by 
construction of a micropatterned structure.  
The main goal of this work is the development of a bioinspired system based on 
adhesion of the grain pollens to the bee’s hair legs. Just as bees are able to capture and release 
the pollen, a micropatterning patch with micropillars (that mimics bees' hair legs) can be 
developed to grab a certain amount of drug. These systems are designed for topical 
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application in skin wounds with a controlled release of antibiotic during the inflammatory 
phase (five days). For this purpose, a system of thin PDMS micropatterned patch with 
micropillars (100 to 550 µm) and tetracycline-loaded microparticles, a common antibiotic 
for skin wounds, is herein developed. Differently sized microparticles were thoroughly 
tested against patches with different configurations in terms of micropillars geometry 
arrangement, height and distance between them, in order to support the hypothesis that grains 
pollen caught by bees' hair legs have similar sizes to the actual leg hair spacing. In fact, 
Amador and co-workers have recently provided physical insight into the critical process of 
pollination and suggest that hair spacing on the body is tuned to accumulate more particles 
and that, to facilitate particles grabbing by the bee’s hair legs, particle size to should be 
comparable to hair leg spacing.[11] Drug release profiles and the antimicrobial activity of the 
obtained systems will also be investigated. Drugs' microparticles will be incorporated in 
micro-patterned soft matter surfaces. The most effective system will be elected after testing 
different particle's size against micropatterned patches with different configurations: 
distance between micropillars and their height; and different geometry arrangement. 
Together with a suitable drug release profile, it is envisaged that the hierarchal patch herein 
developed will be beneficial for an effective treatment of skin wounds. 
For the purpose, this master dissertation development is divided into the subsequent 
chapters: 
 Chapter 1: Motivation, where some introductory notes are given and the main 
goal of this thesis is detailed;  
 Chapter 2: Biomaterials for drug delivery patches, where an insight of current 
state of the existing/commercial available transdermal drug delivery systems 
is provided. Future perspectives are also presented; 
 Chapter 3: Materials and Methods; 
 Chapter 4: Physical supports for immobilization of particles inspired by 
pollination, where a novel and robust bioinspired patch is proposed based on 
the bee’s ability to catch and release the pollen during pollination; 
 Chapter 5: Final Overview, concluding remarks and future prospects. 
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Chapter 2- Biomaterials for drug delivery patches  
Lúcia F. Santos 1, A. Sofia Silva1, João F. Mano1 
1 Department of Chemistry, CICECO – Aveiro Institute of Materials, University of Aveiro, Campus 
Universitário de Santiago, 3810-193 Aveiro, Portugal 
 
Abstract 
The limited efficiency of conventional drugs has been instigated the development of 
new and effective drug delivery systems (DDS). The research and development of 
transdermal DDS have been promoted due to their various advantages such as no pain and 
less frequent and greater flexibility of dosing.  
The simple design, application and lower cost of patches, makes the transdermal 
DDS the best seller of the market. Patches are based on passive drug delivery and higher 
drug concentration must be applied to improve transcutaneous fluxes. These devices have 
been produced using either biodegradable or non-biodegradable polymers. The 
biodegradable ones have been receiving high attention due to their safety, biocompatibility, 
low toxicity and controlled degradation by human enzymes on water. On the other hand, 
non-biodegradable polymers are related to higher risk of skin irritation. However, patches 
based on these materials are the most currently available patches in the market and allow 
greater mechanical resistance and flexibility and non-degradation over the time. 
Furthermore, patches with higher drug concentration have been achieved with these non-
biodegradable polymers. Drug particles have also an important role in patches production. 
Low size and pre-fabrication of drug carriers not only enhanced drug solubility and 
permeation but also allowed a more controlled drug release over the time.  
This review highlights the latest development of patches for drug delivery, focusing 
on the different materials that have been proposed and their combination with drug carriers.  
Key words: Drug delivery systems, trandermal delivery, patches, polymers, skin, drug 
carries.
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1. Introduction 
Drug delivery systems (DDS) has been appointed as an effective way to improve the 
pharmacological and therapeutic properties of drug. These systems not only facility the 
handling and administration of drugs and regulate the local or systemic release, but also help 
the drug to overcome certain barriers and fit the release process to specific therapeutic 
demands.[1] Skin allows a large and readily accessible surface area for application and 
absorption of a patch-like device to its surface, constituting a non-invasive procedure that 
will promote a continuous intervention.[2] In the last years, transdermal drug delivery has 
been exploited as a successful controlled drug release platform that have received regulatory 
approval for a series of products. [3] Transdermal DDS must be applied when a drug has a 
significant first-pass effect in the liver, being prematurely metabolized. Transdermal 
delivery allows for less frequent dosing or steady delivery profiles and may be easily applied 
without pain.[4,5] 
Distinct designs of transdermal DDS have been proposed from the humblest system, 
based on passive drug delivery with little/no permeation enhancement, to more complex 
transdermal DDS that enables the delivery of small molecules and macromolecules.[6] The 
choice among these patches can mostly depend on the drug properties (e.g. molecular weight 
and physicochemical characteristics), as well as the required amount and release profile to 
accomplish an effective treatment.[4] Drug carriers (either at nano- or micro-scale) can be 
incorporated in patches in order to improve drug pharmacological properties, prompting a 
more efficient treatment of such device.[1]  
This review section will highlight the efforts developed in last years regarding the 
production of patches with different designs and their potential application in drug delivery. 
Pros and cons of currently available systems will be discussed and future prospects will be 
discussed. 
1. Drug Delivery Systems 
Conventional (“free”) drugs exhibit some limitations that can be improved through 
their incorporation in DDS. The chemical nature of the drug molecule can be responsible for 
its poor solubility resulting in drug precipitation when in aqueous media. The use of drug 
carriers such as lipid micelles or liposomes among others, can surpassed this major limitation 
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improving drug solubility.[7] Another common problematic is the expeditious breakdown of 
the drug in vivo due to physiological conditions like pH. Such degradation, that leads to a 
notable loss of drug activity, can be prevented through the use of DDS that will protect the 
drug from premature degradation.[8] Moreover, drug carriers empower less non-specific 
distribution, reducing unwanted/toxic side effects in healthy tissues. DDS can be designed 
to improve selectivity towards the targeted tissues (like for instance, ligand-mediated 
targeting), allows for an increased drug concentration in the specific site of action, enhancing 
drug effects in the diseased area.[9,10] Through the association of particular carrier systems 
with conventional therapeutic molecules, properties such as pharmacokinetics and 
biodistribution are strongly improved allowing a higher specific response to the target 
tissue.[11]  
2. Transdermal Drug Delivery Systems 
Many efforts have been developed to promote topic/transdermal drug delivery. 
However, systemic route still the main drug administration strategy. A drug administered 
through the systemic route reaches the systemic circulation (blood) inducing, therefore, a 
systemic action. On the other hand, drugs given by the topical route are mainly applied on 
skin or mucous membrane, promoting a localized action. [12,13] 
Skin exhibits a large and readily accessible surface area for the absorption and/or 
application of a patch-like device in a non-invasive procedure, promoting a continuous 
intervention (system repositioning, removal or replacement). These devices are not capable 
of rapid drug input but are usually designed to retard and sustain the delivery of the drug.[4] 
Transdermal drug delivery allows less frequent dosing with a continuous delivery and can 
be applied to avoid the first-pass effect in the liver, where drugs can be prematurely 
metabolized.[4] However, these systems also present some drawbacks such the potential toxic 
effect of the drug.[6]  
In the last years, transdermal drug delivery has been exploited as a successful 
controlled drug release platform that has received regulatory approval for several products, 
with a large majority already available in the market.[3] The worldwide transdermal patch 
market approaches £2 billion in USA, yet restricted to ten drugs - scopolamine (hyoscine), 
nitroglycerine, clonidine, estradiol (with and without norethisterone or levonorgestrel), 
testosterone, fentanyl, nicotine and lidocaine.[14] There are several parameters that affect the 
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delivery of the drug from the patch to the skin. Absorption, for instance, depends on the site 
of application, thickness and integrity of epidermidis, size of drug molecule, permeability of 
the drug delivery membrane, state of skin hydration, pH of the drug, drug degradation by 
skin flora, lipid solubility and body conditions, such as body temperature and some additives, 
that are responsible for blood flow alteration.[15,16] Skin thickness and blood flow are two 
parameters that vary with age and are responsible for different responses to the same 
transdermal device, a notable effect on drug’s pharmacokinetics.[15] 
Transdermal devices can be divided based on their design in reservoir-type and 
matrix-type patches as briefly represented in Figure 2.1.[17] The reservoir-type patches allow 
the sustaining of the drug in a solution or gel, and its delivery is governed by a rate-
controlling membrane that is positioned between the drug reservoir and skin.[18] On the other 
hand, matrix-type patches, that were introduced in the 80s,[19] are characterized by a simple 
design based on the incorporation of drug in an adhesive. A mechanical backbone is used as 
an outer layer to prevent loss of drug from the adhesive. This design does not involve rate-
controlling membranes and the rate of drug delivery is achieved through skin 
permeability.[15] The reservoir-type patches have been showing more advantages in terms of 
formulation flexibility and tighter control over delivery rate.  
 
 
3.  Barriers to transdermal delivers 
Skin is a highly efficient barrier that limits molecular transport both from and into 
the body, preventing molecular permeation. This natural barrier avoids the penetration of 
foreign molecules such as the flux of toxins, while minimizing the loss of water.[20] Skin is 
composed by multi-layers, as displayed in Figure 2.2. On skin’s outer surface there is a non-
living layer of keratin-filled cells surrounded by a lipid-rich extracellular matrix named 
stratum corneum (SC), an extremely thin biomembrane (approximately 100 µm) that is 
1 2 
Figure 2.1. Schematic representation of patches design 1. Reservoir-type 2. Matrix type. 
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considered the least permeable of the skin layers. SC has been proposed to play an important 
role in the barrier function and is the ultimate stage in the epidemical differentiation process, 
forming a laminate of compressed keratin filled with corneocytes attached in a lipophilic 
matrix. [21] The matrix lipids allow a continuous phase from the skin surface to SC base. The 
intercellular lipid lamellae forms a conduit in which the drugs diffuse to access vascular 
infrastructure and, ultimately, to the systemic system.[4,22] Nevertheless, due to SC high 
diffusional resistance, the transdermal permeation of a large pool of drugs is highly limited 
in a mechanism of passive permeation.[20]  
 
 
Pharmacologically potent drugs requiring small therapeutic blood concentrations (ng 
ml-1 or less), are usually subjected to passive transdermal delivery. The SC is a very selective 
barrier and only molecules with the adequate physicochemical properties can be transported 
across this outer layer.[4,23] The lipophilic nature of SC’s barrier promotes a better 
acceptation of lipophilic molecules. Still, for an accurate passive permeation, the ideal drug 
should be amphiphilic and sufficiently “mobile” to diffuse across the SC. If the drug is only 
Stratum Corneum 
Epidermis 
Dermis 
Cutaneous Microcirculation 
Systemic Circulation 
Subdermal Tissue 
Figure 2.2. Schematic representation of skin layers. 
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hydrophilic, the molecule will be unable to be transfer into the SC. On the other hand, a 
lipophilic drug will tend to remain on the SC layer.[4,24] Solute diffusivity decreases 
exponentially as molecular volume (related to molecular weight) increases. A favourable 
transport across the skin is normally achieved with restriction of drug particles size (less than 
500 Da). Also, an increased drug flux is favoured when saturated drugs’ solution are used. 
Conclusively, in order to improve transcutaneous fluxes it is necessary to increase solute 
concentration and use an amphiphilic drug.[4]  
3.1. Enhancing skin permeation 
Relatively impermeable molecules can be modified in order to improve their 
permeation in skin layers. Drugs per se can be modified, for example, by a derivatization 
strategy to alter the lipophilic nature of the drug. Other chemical modifications as well as 
physical alterations can also be performed in order to improve drugs permeation (Table 
2.1).[4,25] 
However, currently approaches are focused on the enhancement of skin permeation, 
being devoted to the development of new active and passive methods that improve 
membrane’s permeability. Passive methods include the actual vehicles - creams, gels and 
“passive” patches. Some modifications have been proposed such as the use of penetration 
enhancers, supersatured systems or drug carries liposomes. Chemical penetration enhancers 
have the ability of compromising skin’s barrier allowing the entry of poorly penetrating 
molecules through the membrane.[4] Chemicals like alcohols can solubilize and extract lipid 
components of the SC or induce lipid fluidization, therefore increasing permeation. Still, this 
method presents some limitations such as the physiological incompatibility of the high 
concentrated chemical enhancer used to achieve suitable levels of penetration.[26,27] 
Supersatured systems are based on the production of a supersatured drug solution, which is 
a very simple method to increase skin permeation.[28] Commented before, drug carriers 
improve both drug properties as well as their permeation throughout the skin for a targeted 
delivery.[29] Nevertheless, due to skin characteristics (low permeability and diffusion), these 
methods are limited by the amount of drug that can be delivery.[16]  
Nowadays, there are an increasing generation of new therapeutically-active 
molecules with large molecular weight (superior to 500 Da) and mostly hydrophilic. Passive 
methods of skin delivery are not capable to enhance permeation of these large molecules. 
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This problem has been solved through the development of active methods of permeation that 
involve the use of external energy to interfere with the natural barrier of SC to improve 
transdermal transport.[20] Iontophoresis, electroporation, ultrasound, laser radiation, 
radiofrequency, microneedles, skin abrasion, puncture and abrasion, magnephoresis and 
temperature are the main active approaches.[16]  
Some physical enhancement techniques have been applied to allow the penetration 
of emerging “biotechnological” drugs like peptides and oligonucleotides, commonly 
associated to a difficult penetration.[16] Iontophoresis is one of the most common physical 
enhancement technologies and makes use of a small electrical current, at a constant pulse, 
to promote the placement of charged and uncharged species of therapeutic drugs at skin 
surface.[14,30] Electroporation uses high-voltage short-duration pulses in order to create 
regions of membrane permeabilization by the production of aqueous pathways in SC with 
full reversibility within minutes to hours.[25] Ultrasound is also able to compromise the skin’s 
barrier function. This technique applies a frequency greater than 20 kHz and is responsible 
to increase the pore size, promoting alterations in the SC lipid architecture.[31]  Another 
method based on radiation application has been reported. Laser radiation destroys the target 
cells that are related to SC ablation without significant damage on epidermis.[32] 
Radiofrequency is also commonly used for the ablation of malignant tissues due to its ability 
to induce microchannel formation in skin.[33] Microneedle-based device is another 
methodology and consists of a drug reservoir and a set of microneedles that penetrates the 
SC and epidermis to deliver the drug. This type of devices not only presents the ability to 
overcome barriers properties of SC but also allows a controlled rate for local or systemic 
effect. The microneedles create channels on the skin that allow the transport of any topically 
applied drug.[34],[35] Skin abrasion, a common technique used by dermatologists, consists in 
the direct removal of the most superficial layers of the skin in order to increase the 
permeation of the drugs. With this procedure, the diffusion of the drug is not restricted by 
its physicochemical properties.[36] Skin puncture and perforation is another technique that 
uses needle-like structures to promote the disruption of the skin barrier through the creation 
of holes and cuts.[20] The majority of these enhancement techniques are invasive. Pressure 
application has also been appointed as an alternative, providing a non-invasive and simple 
method to enhance skin permeability through increasing of transappendageal route 
(including permeation through the sweat glands and across the hair follicles with their 
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associated sebaceous gland) and drug partition in the SC.[20,37] Another non-invasive 
methodology is magnetophoresis that consists in the application of a magnetic field to 
enhance the diffusion of a diamagnetic solute across the skin.[38] Temperature has also an 
important role in the permeability enhancement. The increase of the temperature improves 
the drug diffusion and the skin lipid fluidity.[39] 
 
Table 2.1. Advanced techniques to enhance drug delivery via transdermal route. 
Techniques Advantages Limitations 
Passive Methods   
Drug carries (e.g. vesicles) 
Supersaturated systems 
Chemical penetration enhancers 
[16],[27,28] 
Simple methods; 
Extra equipment not required; 
Physiological incompatibility of 
the high concentrated chemical; 
Limited by drug amount; 
Not applied to large and 
hydrophilic drugs; 
Active Methods   
Electroporation[25] 
Versatility; 
Transient changes in tissue; 
Non-target transport; 
Invasive; 
Require several applicator; 
Iontophoresis [14,30] 
Simple design; 
Without pain sensation; 
Involves skin structural changes; 
Possibility of burns; 
Drug solution must be sufficiently 
ionized;  
Invasive; 
Ultrasound [31] 
No 
permanent loss of skin barrier; 
Non-invasive; 
Long-time application; 
Laser radiation[32] High precision SC ablation; 
Some damages to living tissue; 
Invasive; 
Radiofrequency[33] 
Single applicator;  
Targeted (not affect in proximal 
muscles); 
Involves skin structural changes; 
Invasive; 
Microneedles[34],[35] 
Minor skin abrasion; 
Controlled drug release; 
Painless; 
Local infections at the needle–
skin interface; 
Invasive; 
Skin abrasion[36] 
Little damage to deeper tissues; 
Common cosmetic procedure;  
Non-target drug delivery; 
Invasive; 
Skin puncture and perforation[20] 
Wide drug range; 
Painless; 
Invasive; 
Magnetophoresis[38] 
No effect on the skin structure; 
Non-invasive; 
Lacks in safety research;  
Temperature[39] 
No damages to the deeper 
tissue; 
Non-invasive; 
Skin structure alteration at highest 
temperatures; 
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4. Transdermal drug delivery patches  
According to Prausnitz and Langer, transdermal delivery systems can be divided in 
three generations of development. The majority of the actual patches are within the first 
generation class that carry specific types of drugs (e.g. sufentanil and granisetron) able to 
cross skin barriers at a therapeutic level but with little or no enhancement. Moreover, this 
type of patches is limited to drugs with suitable properties such as low-molecular weight, 
lipophilic and efficacious at low doses. The second generation is characterized by some 
improvements that allow the delivery of small-molecules by increasing skin permeability. 
Third generation patches enable the transdermal delivery of small-molecules of drugs or 
macromolecules such as proteins or DNA, and other vaccines through targeted 
permeabilization of the skin’s SC.[40] Table 2.2 summarizes the current transdermal patches 
based on biodegradable and non-biodegradable polymers 
5. Patches based on natural and biodegradable polymers  
Biocompatible and biodegradable polymers, mostly natural ones have been received 
careful attention due to their biocompatibility, low toxicity and susceptibility to degradation 
by human enzymes or by hydrolysis.[41] 
5.1.Chitosan  
Chitosan is a natural biodegradable polymer derived from chitin, with high potential 
in patches application. There are several works based on the development of chitosan-based 
patches. Chitosan possesses a suitable film-forming ability with bioadhesive and absorption 
enhancement capacity.[42] Sigfridsson and co-workers have developed a polymeric patch 
based on chitosan layer and an aluminium backing. This patch incorporated 125 mg of 
Gibenclamide nanocrystals, a hypoglycaemic agent given to diabetic patients. Chitosan 
decreased the usually nanocrystals precipitation and improved skin permeation of 
Gibenclamide by nanosizing the drug.[43] The chitosan transdermal patch presents a solution 
to traditional diabetes treatment that consists in numerous daily injections of insulin, 
affecting the life quality of diabetic patients. In addition, the insulin injections are also 
associated to several adverse effects like insulin resistance, glucose intolerance, weight gain 
and cardiovascular complications.[44–46] 
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One limitation of patches in prolong treatments is the weak adhesion of the patch to 
the skin. A novel approach to enhance adhesion and improve mechanical properties of 
chitosan patches was proposed by Anirudhnan and co-workers and consisted in the grafting 
of chitosan with glycidyl methacrylate (GMA) and butyl methacrylate (BMA).[47] Amine 
functionalized hyaluronic acid (HA) (by hydrophobic modification) was used to encapsulate 
lidocaine, which is a poor water soluble drug used to neuropathic pain and presents a set of 
secondary effects. The encapsulate drug microparticles were then dispersed in the modified 
chitosan matrix. This combination offered a matrix with improved mechanical properties, 
drug retention behaviour and good storage over the time. Chitosan modification with another 
acrylate confirmed the possibility to improve the mechanical properties of chitosan patches. 
Modified chitosan with poly(2-hydroxyethylacrylate) (PHEA) offered an efficient 
transdermal hydrogel patch for levofloxacin (an antibiotic) to wound infection treatment. 
PHEA enhanced the patch flexibility as well as the hydrogel itself, allowing a higher 
swelling ability associated with increased drug skin permeation.[48] However, some 
limitations are observed in crosslinked chitosan patches. Higher crosslinking ratio was 
associated to a decrease in swelling ratio. Moreover, other limitations were herein also 
demonstrated such as the restrict drug content (only 5% of the patch) and the hydrogel 
degradation along the time.  
Another modified chitosan matrix was introduced by Hye Kim and co-workers. A 
silver hybridized porous chitosan-based patch was developed with high mechanical strength 
and drug delivery efficiency with Rhodamine B (5 mg mL-1) as a model molecule.[49] Silver 
metal has been appointed as strong bacterial inhibitor with potential applications to prevent 
wound infections. In this work, silver promoted drug release by enhancement of hybridized 
films hydrophobicity, which was related to an increase of SC permeability.  
Chitosan, has also been receiving particular attention for microneedles patches 
applications. Due to the safety concerns associated with microneedles break in the skin, 
biodegradable and biocompatible polymers have been used in order to overcome such 
limitations, promoting total dissolution of the microneedles and decreasing the 
contamination risk without waste generation.[50] According to Chen and co-workers, 
chitosan microneedles patch showed to be a promising device for sustained delivery of 
hydrophilic macromolecules. Figure 2.3 presents a chitosan microneedles patch and the 
resulting microneedle puncture marks on the skin.  By using bovine serum album (BSA) as 
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a model protein, this patch allowed the encapsulation of fragile macromolecules without 
major changes over the time and enabled a prolonged release (8 days), normally required in 
therapies with these molecules (e.g. vaccines and DNA therapies). BSA was used in order 
to determine the applicability of this system to macromolecules. However, in this specific 
study case, some microneedles fragments remained upon patch removal.[51] Drugs loaded in 
chitosan carriers could be released through swelling and degradation of the chitosan matrix, 
leading to a clear sustained-release effect.[52] 
 
 
More efforts will be needed to improve the properties of chitosan-based patches to 
enhance the drug encapsulation capability and release kinetics, and important properties such 
as adhesion and mechanical properties. Combination with inorganic fillers[53],[54] and the 
nanostructured membranes could be possible.[55,56]  
5.2.Cellulose  
Cellulose is one of the most common polymers in nature and the largest constituent 
of the plants. The last decades revealed that cellulose can be also produced by bacteria. The 
bacterial cellulose has unique physical and mechanical properties, high purity and 
biocompatibility that promote their application in the biomedical field.[57] 
Literature reports show that bacterial cellulose membranes (Figure 2.4) have a 
simple design composed by a single layer with straightforwardness and effeteness to absorb 
executes and adhere to irregular surfaces, a critical parameter to several clinical situations 
such as burns and wounds.[58,59] Comparing to the conventional routes, some limitations were 
appointed to these patches. Particularly, Trovatti and colleagues obtained low drug flux of 
Figure 2.3. Chitosan microneedle patch a. Bright-field micrograph of microneedle puncture marks on the 
skin b. Scanning electron micrograph of an inverse replica of skin surface after insertion and removal of 
microneedles.[51] 
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diclofenac (hydrophilic drug), an anti-inflammatory normally administrated as a gel.[59] The 
lower flux was explained through the resistance promoted by the complex tridimensional 
network of these membranes to the diffusion of drug molecules. The chemical properties of 
the drug were also pointed out as a limitation. In fact, lower permeation rates were obtain by 
Silva and colleagues, who incorporated lidocaine hydrochloride in bacterial cellulose 
membranes and compared those results with the ones obtained through the conventional 
administration systems. However, when a lipophilic drug was incorporated a three-time 
higher permeation rate was achieved.[58] These membranes can be applied to pathologies that 
require lipophilic drugs and long-term release. 
 
 
Cellulose can be also applied to transdermal hydrogel patches. Ahmed and El-Say 
have reported two cellulose derivatives, hydroxy propyl methyl cellulose (HPMC) and 
hydroxyl propyl cellulose (HPC) that were incorporated with raberprazole- alginate/chitosan 
nanoparticles. HPMC showed higher drug flux than HPC. Microspheres of alginate-chitosan 
have been applied in a wide range of biomedical applications. However, leaching of the drug 
during the formulation process remains the major drawback. The novel approach of drug 
encapsulation developed by the authors enhanced the drug entrapment and permeation 
comparing to the assay with “free” drug (control). However, the diffusion rate was slower 
than the control one.[60]  
These two cellulose derivatives were also used to develop microneedle patches. In 
the work performed by Kim and co-workers, HPMC combined with drug was used for the 
tips and carboxymethyl cellulose (CMC) for needles base. This system allowed a rapid 
release of 179.9µg donepezil hydrochloride to Alzheimer’s treatment with a more effective 
delivery than the conventional oral route. However, the distribution was not uniform and an 
Figure 2.4. Visual images of bacterial cellulose processed and applied as patches.[58]  
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applicator is required to solve this limitation. Furthermore, the patch did not allow the 
loading of high drug amounts but higher patch area can solve this problem.[61]  
Hydroxyl cellulose (HEC) is another cellulose derivative reported in the engineering 
of hydrogel patches, where hydroxyl group allowed an increase of the natural cellulose’s 
solubility. Kong and colleagues described the cross-linking of HEC with HA enhancing skin 
permeation of isoliquiritigenin, which has beneficial effects on cancer treatment. In cross-
linked hydrogels, the drug permeation is limited by the cross-linking degree. HA helped in 
permeation due to the high water retention capacity, which promoted the looseness of the 
skin barrier though skin hydration.[62] HA was also associated to higher permeation in the 
work developed by Korkmaz and co-workers. A dissolving microneedle device was 
fabricated through the combination of carboxymethyl cellulose (CMC) with HA to delivery 
of 0.5 mg anti-tumor-necrosis-factor-alpha (anti-TNF-α), a high weight hydrophilic 
substance that has an important role in autoinflammatory skin diseases. The combination of 
CMC and HA effectively inhibited antibody diffusion from the delivery site, allowing a 
targeted drug delivery. Moreover, both side-effects and loss of drug content are herein 
decreased.[63]  
Due the physical and mechanical resistance of cellulose and their functionalized 
forms, could be developed patches with different design and applicability.  
5.3.Starch 
Pure starch is a rigid and brittle polymer with poor film-forming properties. These 
features can be improved by physical blending with other biomaterials improving the 
mechanical functionality of starch.[70,71] An efficient hydrogel patch of starch nanocrystals 
was recently developed by Bakrudeen and co-workers that allowed the incorporation of a 
high amount of acyclovir (200 mg) to antiviral treatment. This hydrogel patch disclosed both 
good adhesion and stability due to nanocrystals properties, such as crystallinity and 
morphology. However, the amorphous structure of starch limited its effect as a plasticizer.[72] 
Moreover, the mixing of starch with other polymers decreased the drug amount embedded. 
In fact, Ling and Chen proposed a dissolving starch-based microneedles device conjugated 
with gelatin to delivery insulin, achieving only 2 mg of drug incorporation within the patch. 
Nevertheless, when compared to conventional treatments, a faster release and similar insulin 
plasma concentration were achieved, despite of the delayed drug effect.[73]  
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5.4.Pectin 
Pectin and their derivatives are commonly used in hydrogel patches. Hadebe and 
colleagues have developed an amidated pectin hydrogel patch that allowed an efficient 
delivery of insulin (16.8 µg insulin/kg patch), used in diabetes treatment.[44] The hydrogel 
showed good stability and promoted prolong controlled insulin release. However, the non-
availability of insulin-containing dermal patches into unit dosage was pointed as possible 
limitation in patient acceptance. The incorporation of higher amounts of drug was proposed 
by Mavondo and Tagumirwa that engineered a pectin-based hydrogel that allowed the 
inclusion of 5 mg asiatic acid (AA)/kg patch. Drug bioavailability was enhanced with higher 
drug flux i.e. great permeability. However, higher levels of drug can turn out to be toxic and 
exacerbate the disease.[69] 
5.5.Hyaluronic acid  
HA is a biopolymer commonly used in fabrication of hydrogel patches. It can also be 
combined with other polymers and be also applied for solid or dissolving microneedle 
device.[64,65] When compared with dissolving microneedles, solid ones demonstrated less 
capacity for drug incorporation within the patch. According to Witting and colleagues, only 
23 µg of asparaginase (a model enzyme) were incorporated in a solid commercial 
microneedle device (1 cm2) through the conjugation of HA with the enzyme. Although the 
enzymatic activity was maintained by months, microneedle insertion caused a slight skin 
irritation.[65] On the other hand, Mönkäre and co-workers reported that when HA with 
Immunoglobulin (IgG) was used in dissolving microneedles, a higher amount of drug was 
incorporated (10 mg). Skin reactions were also overcome with dissolving microneedles 
patches. Even though IgG showed no conformal changes or protein aggregates, the patch 
showed limited use in treatments that need continuous long-term release because of the faster 
microneedle dissolution. Figure 2.5 elucidates the process of microneedles dissolution from 
the outermost layer to the inner one.[64] 
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In order to improve both resistance and mechanical properties of dissolving 
microneedles patches, Liu and colleagues developed a HA microneedle patch reinforced 
with polyethylene terephthalate (PET) adhesive. This patch improved the permeability of 
high molecular weight drugs such as fluorescein isothiocyanate-labeled dextran, a common 
model molecule. However, low drug amount was incorporated (250 µg) and long-time 
dissolution of base plate (made of PET) was achieved, which results in waste generation. 
Skin irritation was another limitation promoted by this type of microneedle patch.[66] 
HA has been approved by FDA to be use as dermal filler, becoming a polymer with 
high potential application to the fabrication of microneedle or another devices to skin 
insertion. 
5.6.Natural Rubber 
Natural rubber is known by its interesting features such as low cost, biocompatibility, 
high mechanical resistance, ease manipulation and film formation. However, some works 
reported allergic reactions induced by natural rubber. Suksaeree and colleagues have 
reported a methodology to solve such problematic that involves the use of deproteinised 
natural rubber (DNR).[67] Several studies focus on the development of efficient polymeric 
patches based on DNR to nicotine delivery, commonly used to smoking cessation. This 
material is used in the fabrication of matrix and reservoir-type patches.[67,68] Nicotine 
treatment requires the incorporation of high drug amount to support a continuous release. In 
the case of matrix patches, lower drug incorporation was achieved (2.5 mg.cm-2). Patches 
with or without backing layer were tested and the addition of backing layer significantly 
increased the release of the drug.[67] Pichayakorn and co-workers developed a reservoir-type 
patch with the same material and drug, and a higher drug amount was incorporated (4.25 
mg.cm-2).[68] However, the impossibility of storage at high temperatures represents a major 
drawback for the use of this type of patch.  
Figure 2.5. Schematic dissolution of microneedles, which sequentially dissolution from the outermost layer 
to the inner one.[75] 
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DNR could be blended with another polymers to improve their properties and allow 
the development of distinctive patches design.  
5.7.Polycaprolactone  
An efficient dissolving microneedle patch for the delivery of hydrophilic molecules 
was developed by Ko and colleagues through the combination of polycaprolactone (PCL) 
and poly(ethylene glycol) (PEG).[79] A model molecule like rhodamine was used and short-
term transdermal delivery was achieved. The patch had the ability to incorporate 0.6 mg of 
drug, higher than most of previously referred patches. However, when hydrophilic molecules 
with high molecular weight were used, a slower release rate was achieved. Besides that, the 
patch allowed the permeability enhancement of hydrophilic molecules, commonly 
impermeable in SC. Other biodegradable aliphatic polyesters should be more explored in the 
future, as many biomedical products based on such polymers are already approved in the 
clinics. 
6. Patches based on non-biodegradable polymers  
Non-biodegradable materials are normally associated with a higher risk of skin 
irritation and their use is more limited when compared to natural polymers. In the case of 
solid microneedles patches, some materials can remain inside the skin promoting a set of 
adverse reactions. These non-dissolving microneedles generate waste that implies treatment 
to prevent the risk of disease dissemination. Besides their disadvantages, patches based on 
synthetic materials are commercially available and allow greater mechanical properties, such 
as mechanical resistance and non-degradation over time.[81] These materials are widely used 
in drug-in adhesive (DIA) and microneedles patches. DIA patches consist in the 
incorporation of a drug and possible additives in pressure sensitive adhesives (PSA) that is 
Figure 2.6. Schematic representation of DIA patches. 
CHAPTER 2 BIOMATERIALS FOR DRUG DELIVERY PATCHES 
 
22 
 
limited by a backing film and release liner (Figure 2.6). Three types of PSA have been used 
in transdermal patches such as polyisobutylenes (PBI), silicon and acrylics.[82] 
6.1.Polyvinyl alcohol  
PVA has been showing high potential in biomedical applications due to its rubbery 
elastic nature, non-toxicity, non-carcinogenicity and rapidly acceptance by the body.[74] The 
application of PVA in microneedles devices is limited as a result of the insufficient 
mechanical strength to puncture the SC and their low solubility, which reduces the drug 
release rate. One solution for this problem was proposed by Lau and colleagues, through the 
combination of silk fibroin with a PVA pedestal in a multi-layered microneedle patch. The 
flexible pedestal provided suitable skin adhesion and stress dispersion, while silk fibroin 
improved drug loading by increasing contact surface. A fast release of insulin (1.0 mg) was 
achieved with better regulation of the dissolution rate. Nevertheless, storing the patch at dry 
conditions may represent a limitation since it represents a costly expense.[75] Similarly, Chen 
and colleagues obtained a support structure through the association of PVA, 
polyvinylpyrrolidone (PVP) and a polyglycolide (PGA) hydrogel with insulin for the 
treatment of diabetes. This collective patch allowed an incorporation of 2.0 mg of insulin 
and enabled a full drug release with complete microneedles insertion. Besides hydrogel’s 
degradation at low concentration, PGA also showed an important role in accelerating the 
wound healing process, induced by microneedles insertion.[76] Higher drug amount was 
incorporated in the patch with the combinations of chitosan-polyvinyl alcohol (CS-PVA) 
hydrogel cross-linked with Maleic anhydride. The drug permeability was enhanced with 
PVA content by increasing hydrogel swelling and pore formation. Although the 
incorporation of 10 mg of alprazolam offered a solution to the conventional treatments, by 
preventing their unwanted side effects, the drug flux was significantly low and not 
proportional to the entrapped drug amount.[77] 
PVA can be also applied to polymeric patches. According to Kataria and colleagues, 
the combination of PVA with alginate allowed the fabrication of an efficient patch based on 
nanofibers with total entrapment of the drug within the nanofibers. The delivery of 
ciprofloxacin promoted a complete and fast wound healing, preventing from infection. The 
nanofibers were able to absorb exudates, adjusting to wound moisture through their 
extensive surface and microporous structure.[78] 
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Due their characteristics, PVA has been applied to the fabrication of distinct patches 
from the supporting structures of microneedles to hydrogels. In addition, PVA could be 
blended with another polymers to construct patches with ideal features. 
6.2.Polyvinylpryrrolidone  
Most treatments, such as the ones for cardiovascular diseases, have the need for 
simultaneous administration of multiple drugs. Quinn and colleagues reported a dissolving 
microneedle patch based on the combination of two biocompatible polymers, 
polyvinylpryrrolidone (PVP) and poly (methylvinylether/maleic acid).[80] This patch 
allowed the simultaneous delivery of aspirin, lisinopril dihydrate and atorvastatin calcium 
trihydrate, with rapid microneedles dissolution. Nevertheless, the patch showed some 
limitations such as poor delivery of hydrophobic drugs, skin irritation after patch’s regular 
use and increased drug concentration after only 48 h, mainly due to water evaporation during 
the drying period of the patch.  
6.3.Acrylic-based polymers  
Acrylic and their derivatives are commonly used in commercial patches. One of most 
sold transdermal patches are contraceptive devices. A DIA patch with acrylic PSA was 
developed for the efficient delivery of ethynyl estradiol and levonorgestrel.[83] These 
hormones were applied to female contraceptive devices.  Long-time release and great storage 
in a high range of temperatures, essential conditions to contraceptives patches, were 
successfully achieved. A set of commercial acrylic patches were used and the results showed 
that the higher drug release was achieve with an acrylic patch functionalized with hydroxyl 
group when compared to acrylic patches functionalized with carboxyl groups. Other recent 
studies support this conclusion. Jung and colleagues, for instance, reported a DIA patch 
based on acrylic PSA for fluoxetine delivery, commonly used for depression treatment and 
other psychological diseases.[84] Conventional treatments present several side effects mainly 
caused by variable plasma drug levels. In this work, a constant high amount of drug was 
applied to promote prolong release with constant plasma drug level. Drug flux was increased 
as the drug content also increased from 1% to 20 % (w/w). These acrylic patches 
functionalized with hydroxyl groups also presented a good storage capability while 
preventing drug crystallization. However, above 20% content, crystallization of the drug had 
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been observed. The transdermal patch developed by Xi and colleagues allowed an effective 
delivery of anastrozole (2 mg), a drug commonly used in breast cancer treatment.[85] 
However, this drug frequently lacks in specific targeting, being responsible by several 
damages to healthy tissues. The conjugation of anastrozole with DIA patches allowed the 
delivery of a high amount of drug in the site of action. Interestingly, non-functionalized 
acrylic patches showed a higher drug release, when compared to any functionalized ones, 
mainly due to the lack of interactions between the drug and the patch. Adverse skin reactions 
attributed to the residual adhesive, are the critical limitations of this type of patches. 
Additionally, some authors confirmed that acrylic patches with functional groups showed 
lower drug entrapment.[86,87] D-threo-methylphenidate (1.1 mg) was incorporated in a DIA 
patch for the treatment of deficit/hyperactivity disorder and although an efficient drug 
absorption into systemic circulation was achieved, drug plasma concentration was lower 
than the conventional oral route [87]. The high patient compliance and the non-invasive nature 
of these patches have been increasing the number of cases of dose dumping. Fentanyl, a drug 
commonly administrated to pain symptoms and with big interest in obtaining fast-on-set 
euphoria, was incorporated in a geopolymer, priory to its inclusion in acrylic patches, 
increasing its resistance to tamper, preventing its abuse without compromising the efficiency 
of drug delivery. This device allowed the effective delivery of a high amount of drug (149 
mg) without compromising the security of these patches. The patches, however, did not show 
resistance to acidic nor ethanol solutions.[86] 
Acrylic patches can also be applied in microneedles devices. The work developed by 
Guo and co-workers combined the properties of a hydrogel with the solid support of silicon 
microneedles.[88] This combination allowed the reduction of normal dose of hepatitis B 
antigen in hepatitis B treatment from 100 µg to 25 µg. The patch promoted higher antibody 
concentration by increasing skin permeability though the combination of hydrogel and solid 
microneedles. Nonetheless, the loss of antibody activity with increments of temperature 
limits the use of this device with sensitive macromolecules. A novel approach to stabilize 
such type of macromolecules was reported by Qiu and colleagues and consisted in the freeze 
drying of poly(acrylamide-co-acrylic acid), that enabled the maintenance of proteins stability 
as well as an easier handling and storage.[89] Such freeze dried patches, however, can only 
be used with high drug amount. When lower amount was applied, loss of drug activity was 
achieved. Nevertheless, this combination of an hydrogel patch and a microneedle device 
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resulting in a powerful device able to incorporate high amounts of insulin (150 mg), 
representing an effective treatment to diabetes.  
Acrylic PSAs functionalized with different groups could have distinct effect on drug 
release through the variation of the three-dimensional network of the polymer chains. 
6.4.Polyisobutylenes  
Contraceptive devices based on the delivery of ethynyl estradiol and levonorgestrel 
were also reported by Schulz and colleagues, where acrylic PSA was changed to 
polyisobutylenes (PIB). Both devices allowed a long-time release and improved storage in a 
wide range of temperatures, which is a requisite for this type of applications. However, 
ethynyl estradiol and levonorgestrel are not soluble on PIB. To solve this problem, drug 
adsorbates were incorporated onto crospovidone into the PIB blends and an increase of drug 
release was achieved. Moreover, the drug flux was lower than the one in acrylic patches. 
The main explanation is the continuous binding of the drug to crospovidone particles (CPVP) 
due to the low solubility of the drug in the adhesive.[83] 
PIB matrices with different molecular weight could vary the drug release, enabling 
the construction of different patches with sustained and controlled release. 
6.5.Silicon  
A silicon microneedles patch can incorporate higher drug amount than the silicon 
patch combined with an acrylic hydrogel proposed by Guo and co-workers,[88] previously 
mentioned. According to Pamornpathomkul and colleagues, a silicon microneedle patch is 
able to incorporate, 2.5 mg of fluorescein-isothiocyanate, a model molecule. The 
combination of solid microneedles with low-frequency sonophoresis allowed the 
enhancement of skin permeability. However, the extra equipment required also implies high 
costs for the final product.[90] 
The mechanical resistance and great storage capability of silicon allow their 
application to the construction of robust patches devices.  
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Table 2.2. Current transdermal patches based on biodegradable and non-biodegradable polymers. 
Patches 
Active 
compound 
Patch Size Dose  Design Advantages Limitations Application Reference 
Biodegradable Materials 
Cellulose  
Bacterial 
Cellulose  
diclofenac 0.95cm2 0.5-1% 
Polymeric 
one layer Homogenous flexible 
Adhere to irregular skin 
surfaces 
Lower permeation 
Long time-release 
Anti-
inflammation  
[58] 
lidocaine 
hydrochloride  
0.95cm2 2% Polymeric 
one layer 
[59] 
ibuprofen 0.95cm2 1% 
Alginate 
chitosan 
nanoparticles 
(HPMC or 
HPC patches) 
rabeprazole 1.76 cm2 - 
Hydrogel and 
cellulosic 
membrane 
Enhancement of the drug 
entrapment and permeation. 
Slow diffusion 
Controls the 
gastric acid 
secretion 
[60] 
HA-
hydroxyethyl 
cellulose 
isoliquiritigenin - 0.5 mM 
Hydrogel and 
cellulosic 
membrane 
Improvement of skin 
permeation 
Lower drug 
penetration  
Cancer 
treatment 
[62] 
HA and CMC 
Anti-tumor-
necrosis- 
factor-alpha  
- 0.5 mg 
Polymeric 
Dissolving 
microneedles 
No inhibition of the binding 
affinity of anti-TNF-α-Abs 
Increased antibody residence 
time 
Lower drug 
incorporation 
Auto 
inflammatory 
skin diseases 
[63] 
HPMC and 
CMC  
Donepezil 
hydrochloride 
0.56 cm2 179.9 µg  
Polymeric 
Dissolving 
microneedle  
More efficacy with same dose 
of drug 
Rapidly release 
Necessity of 
applicator  
Low drug amount 
Alzheimer’s 
disease 
[61] 
Chitosan 
Silver 
hybridized 
porous 
chitosan-
based 
Rhodamine B 0.4 cm2 500 µg/ml Polymeric 
Silver promoted increase of 
drug release and the 
hydrophilicity  
Understand the silver 
interaction with 
chitosan to improve 
their bond strength  
Model 
molecule 
[49] 
Chitosan and 
HA 
lidocaine 8 cm2 1 mg Polymeric 
Good storage over the time 
Improved the mechanical 
properties and drug retention  
Mechanical 
variations of the 
patch over the time 
Neuropathic 
pain 
[47] 
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Chitosan 
Bovine serum 
albumin (BSA) 
- 
0.15% 
 
Microneedle  
Encapsulation of fragile 
biomolecules without 
considerable exchange 
Long-time release  
Reaming of 
microneedles 
fragments 
Standard 
biomolecule 
[91] 
Chitosan 
Glibenclamide 
(nanocrystals) 
1 cm2 125 mg 
Polymeric  
 
Chitosan decreases 
nanoparticles precipitation 
Improvement 
permeation via nanosizing 
Better patient compliance  
Lower patch 
concentration 
Diabetes [92] 
Chitosan with 
PHEA 
levofloxacin 1 cm2 5% Hydrogel 
PHEA enhances the flexibility 
Short time-release 
Hydrogel 
degradation 
Limitation of drug 
concentration 
Wound healing 
Antibacterial 
activity 
[93] 
Starch 
Starch 
nanocrystals 
acyclovir - 200 mg Hydrogel  
Good adhesion 
Better stability  
Amorphous starch 
limited its plasticizer 
effect 
Antiviral [72] 
Starch and 
gelatin  
Insulin 
(biomolucule) 
- 2 mg 
Polymeric 
Dissolving 
microneedle  
Quickly release  
Similar results to conventional 
routes  
Good insulin storage 
Minimum plasma 
glucose level was 
achieved later than 
by insulin injection 
Diabetes [73] 
Pectin 
Pectin asiatic acid 4 mm2 5mg/kg pectin Hydrogel 
Enhancement of Asiatic acid 
bioavailable 
Higher levels of AA  
be toxic and 
exacerbate disease 
 
Malaria 
prevention and 
treatment 
[69] 
Amidated 
pectin 
insulin - 9.57-16.80 µg/kg Hydrogel 
Prolong controlled insulin 
release 
Good hydrogel stability 
Not available 
patches into unit 
dosage forms. 
Diabetes [44] 
HA 
HA asparaginase 1 cm2 10-23 µg 
Coated in 
solid 
microneedle  
The protein activity was 
maintained for months 
MN insertion caused 
a slight skin 
irritation 
Vaccination  [65] 
HA IgG - 2-10 mg 
Polymeric  
Dissolving 
microneedle  
Without antibody conformal 
changes   
No  protein aggregates  
Not allowed 
continuous delivery 
 
Vaccination  [64] 
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HA and PET 
fluorescein 
isothiocyanate-
labeled dextran 
250 µg 
278 µgcm-2 
4 cm2 
Polymeric  
Dissolving 
microneedle  
Improved permeability of 
high molecular weight 
drugs 
Long-time release 
Skin irritation  
Model 
molecule 
[66] 
Rubber 
Deproteinised 
natural 
rubber 
nicotine 
- 4.25 mgcm-2 
Polymeric 
Reservoir 
type 
Rubber showed excellent 
properties  
 
Variation on rubber 
properties  
Not be storage at 
high temperature 
Cessation of 
smoking 
[68] 
70.88 cm2 2.5 mgcm-2 
Polymeric 
Matrix type 
Slower release and 
skin permeation without 
backing layer  
Lower drug 
concentration 
[67] 
PCL 
PCL/PEG Rhodamine 6G 0.6 mg  0.91 mm2 
Polymer 
Microneedle 
Short-term  delivery of 
hydrophilic biomolecules 
Slower release of 
high weigh 
molecules  
Model 
molecule 
[79] 
Non Biodegradable Materials 
PVA 
Poly vinyl 
alcohol (PVA) 
and alginate 
nanofiber 
ciprofloxacin 4 cm2 35 mg/L Polymeric 
Entrapment to nanofibers of 
100%  of loaded drug 
Gelation of alginate 
at low polymer 
concentrations 
Nanofibers 
degradation 
Long-time release 
Wound healing [78] 
Maleic 
Anhydride 
Cross-Linked 
Chitosan-PVA 
alprazolam 2.54 cm2 10 mg Hydrogel 
Alprazolam permeability 
increased with PVA content 
Better compliance 
Low drug flux 
Anxiety and 
depression 
[77] 
Silk fibroin 
tips supported 
on PVA 
pedestal 
Insulin - 1 mg 
Polymeric 
Multilayered 
dissolving 
microneedle  
Storage ability at room 
temperature  
Better regulation of 
dissolution rate 
Rapidly release  
Storage at dry 
condition  
Diabetes [75] 
PGA and 
PVA/PVP 
Insulin - 2.0 mg 
PGA 
Hydrogel in 
PVA/PVP 
support  
Support structure allowed 
complete microneedles 
insertion  
PGA accelerate wound 
healing  
Degradation at low 
hydrogel 
concentration 
Diabetes [76] 
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Dissolving 
microneedle 
No cold chain storage 
Quickly administration 
PVP 
PVP and 
PMVE/MA 
aspirin 
0.49 cm2 5% 
Polymeric 
Dissolving 
microneedle  
Simultaneous administration 
of multiple drugs 
Rapid dissolution 
Poor delivery of 
hydrophobic drugs 
drug concentration 
by  water 
evaporation 
Regular use 
promoted skin 
reactions 
Cardiovascular 
diseases 
[80] 
lisinopril 
dihydrate 
atorvastatin 
calcium 
trihydrate 
 
Maleic 
Anhydride 
Cross-Linked 
Chitosan-PVA alprazolam 
Insulin 
2.54 cm2 10 mg Hydrogel 
Polymeric 
Multilayered 
dissolving 
microneedle  
Alprazolam permeability 
increased with PVA content 
Better compliance 
Storage ability at room 
temperature  
Better regulation of 
dissolution rate 
Rapidly release  
Low drug flux 
Storage at dry 
condition  
Anxiety and 
depression 
Diabetes 
[77] 
[75] Silk fibroin 
tips supported 
on PVA 
pedestal 
- 1 mg 
PGA and 
PVA/PVP 
Insulin - 2.0 mg 
PGA 
Hydrogel in 
PVA/PVP 
support  
Dissolving 
microneedle 
Support structure allowed 
complete microneedles 
insertion  
PGA accelerate wound 
healing  
No cold chain storage 
Quickly administration 
Degradation at low 
hydrogel 
concentration 
Diabetes [76] 
Acrylic and PIB 
Acrylic 
patches 
anastrozole 1 cm2 2 mg 
Polymeric 
DIA 
Circular 
Sustained and controlled 
permeation of the drug 
Local deposition (Reducing of 
systemic side effects) 
Residual adhesive 
Functional groups in 
acrylic PSAs have 
effect on drug 
release 
Breast cancer [85] 
Acrylic 
patches  
fluoxetine 
2.5 cm2 
and  
100 cm2  
15 mg/kg 
(5%) 
Polymeric 
DIA 
Plasma concentration equal to 
oral delivery 
Long-time release 
Not variable plasma 
concentration 
High drug 
concentration 
promotes 
crystallization  
Serotonin 
reuptake 
inhibitor 
[84] 
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Acrylic patch 
with 
geopolymer 
particles 
Fentanyl 4.52 cm2 149 mg Polymeric 
Resistance to tampering  
Plasma drug concentration 
was similar to commercial 
patches 
Low resistance to 
acid pH and ethanol 
solution  
Pain [86] 
Acrylic 
hydrogel and 
silicon  
hepatitis B 
antigen 
1 cm2 
25 µg 
 
Hydrogel  
Microneedle 
 
Increasing of permeation  
Better temperature tolerance  
Reduction of minimum dose 
Loss of antibody 
activity in hydrogel 
patch  at 37°C (45°C 
much higher lost) 
Hepatitis B 
(Vaccination)  
[88] 
Lyophilized 
poly(acrylami
de-co-acrylic 
acid) 
Insulin 1 cm2 
150 mg 
 
Hydrogel 
matrix 
Microneedle 
(pyramidal)  
 
Lyophilized allow more stable 
proteins and easier handling 
and storage 
Possibility of high drug 
amount  
Storage at low 
temperature  
Lower drug amount  
showed loss of 
insulin activity after 
lyophilisation  
 
Diabetes [89] 
PCL/PEG Rhodamine 6G 0.91 mm2 0.6 mg 
Polymeric 
Microneedle 
Short-term  delivery of 
hydrophilic biomolecules 
Slower release of 
high weigh 
molecules  
Model 
molecule 
[79] 
Silicon 
Silicon  
fluorescein 
isothiocyanate  
225 mm2 2.5 mg 
Polymeric 
Microneedle 
with 
sonophoresis 
Enhancement of skin 
permeability  
Increase of drug flux  
Requirement of 
equipment. Not easy 
applicability   
Model 
molecule 
[90] 
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7. Drug particles  
Physical and chemical drug properties greatly impact their release. “Free” drug can 
be directly used in patch production or can be previous encapsulated into carrier systems at 
the nanoscale such as vesicles (e.g. liposomes), nanoparticles or nanofibers. Vesicles, for 
instance, allow the delivery of the entrapped molecules into or across the skin. The first 
papers to report on the effectiveness of vesicles for skin delivery were published in the early 
1980. After this, a large set of carries have been developed to delivery different drugs. These 
carries serve as a rate-limiting membrane barrier for the modulation of systemic absorption, 
providing a controlled and sustained drug release.[94] Nanoparticles have become frequent 
drug delivery vehicles due to their high bioavailability, better encapsulation, control release 
and less toxic properties.[95] Particle size decreasing to the nanoscale is a well-established 
approach to enhance both drug absorption and solubility especially when dissolution rate is 
the limiting factor.[43] However, some polymeric carriers are associated to slow degradation 
and, therefore, prone to accumulate in the body.[96]  
Ali and Hanafy report the use of nanocrystals to increase both drug permeation and 
flux across the skin by a factor of 1.7, when compared to the ‘free’ drug form. Features like 
bioavailibity, surface area and saturation solubility of the poor soluble drug was enhanced 
by size diminution.[92] Microparticles of alginate-raberprazole reinforced with chitosan also 
enhanced the drug entrapment and drug permeation in skin when compared with the assay 
using the non-encapsulated drug.[60] Another example was lidocaine, a poor water soluble 
drug, that was encapsulated in amine functionalized HA microparticles and applied to an 
efficient chitosan patch.[47] The enhancement of drug solubility through encapsulation in 
nano/microparticles was also reported in the PIB patch developed by Schulz and co-workers. 
Ethynyl estradiol and levonorgestrel were not soluble in PIB and their incorporation onto 
crospovidone particles circumvented this problem. These drug carries not only allowed the 
drug solubilisation in PIB but also increased drug release.[83] 
 At last, the use of drug carriers to increase both drug’s solubility and permeation, has 
been showing promising results in the enhancement of drug release.[94] 
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8. Hydrogels vs non-hydrogel polymeric patches  
Hydrogel is a water-swollen, and cross-linked polymeric network produced by the 
simple reaction of one or more monomers.[97] Hydrogels have received high attention in the 
past 50 years, due to their exceptional promise in wide range of applications. [98] The first 
application of hydrogels in biomedical devices were performed in the 60s by Wichterle and 
Lím. [99] Hydrogels’ highly valuable characteristics have been stimulating a growing 
research for a wide range of applications in the biomedical field: degradable nature, the 
ability to be injectable or pre-fabricated, the shape and surface, the openness of the pores, 
water content, chemical modifications with enhancement of drug attachment, the 
sterilizability and the possibility to add bioactive compounds.[100,101] Hydrogels based on 
natural, synthetic or combined polymers have been applied for cells encapsulation[102] and 
tissue engineering,[103,104]with an important role in repairing and regenerating tissues and 
drug delivery.[105] Hydrogels can be applied through different physical forms such as 
previous solid forms, microparticles, coatings, membranes and sheets. The last ones are 
known for their important role in transdermal drug delivery as reservoir in patches. 
Hydrogels’ application in drug delivery systems is related to its characteristics.[106] 
The high water content in a hydrogel limits nutrients’ permeation into and out of the gel. It 
also allows the drugs’ permeation enhancement reaching an equilibrium swelling level. The 
amount of water in the hydrogel determines both absorption and diffusion of the solutes 
through it. Also, drug release depends on the pore volume fraction, pores size and their 
interconnections, molecule size, and the type and strength of the interactions between the 
drug and the polymeric chains.[100] However, hydrogels also exhibit some limitations to their 
application. In most cases hydrogels can be hard to handle, since they are usually mechanical 
weak, difficult to sterilize and in some cases the loading of the drugs can be problematic in 
prefabricated matrix. The quantity and homogeneity of drug delivery may be limited, 
especially with hydrophobic drugs. Furthermore, common hydrogels with high water content 
and large pore size result in rapid drug release, which limits the applicability to sustained 
drug delivery.[107] 
Polymeric patches were the first to reach the market by the introduction of the 
scopolamine patch.[19] These patches are mainly present in matrix systems, where polymers 
have important role and act as PSA which are capable of sticking to the skin by applying a 
light pressure and can be removed without leaving any visually noticeable residue. However, 
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ones can also be applied to engineer reservoir type patches.[108] Natural (e.g. cellulose, starch, 
chitosan) and synthetic polymers (e.g., PVA, PCL, PVP) have been widely used in different 
design patches. However, the ultimate product  should remain stable in storage conditions 
over a long period.[97] Non-hydrogel polymeric patches often meet these needs. They show 
higher mechanical resistance, an easier handle and long storage time. In case of long-term 
treatments, stable patches are required, preserving patch properties along the treatment. This 
problem is also solved through non-hydrogel polymeric patches. The limitation of these 
patches is usually by the restriction of the drugs applied. Hydrogels show higher drug 
permeation, especially in case of molecules with high molecular weight or hydrophilic 
properties. Nonetheless, higher drug incorporation can result in drug crystallization.[109] 
According to their properties, both hydrogels and polymeric patches can be used to 
engineer efficient transdermal patches. The choice of arrangement strongly depends on drug 
properties, the amount of drug needed and the required time of treatment.  
9. Commercial patches 
The desired new product must present a reasonable cost and meeting the unmet 
medical needs. The first transdermal patch was approved more than 30 years ago for the 
treatment of motion sickness. Approximately two dozen molecules have been approved for 
transdermal administration by the regulatory authorities to reach the market. Most of these 
drugs are for prescription use only, with many being available as generic patches following 
patent expirations.[110] Table 2.3 summarizes these available drugs approved by Food and 
Drug Administration (FDA) and the main characteristics of these transdermal patches: 
indication, design, dose and patch size and duration of the application.  
Although the vast number of patches in the market, scopolamine (hyoscine), 
nitroglycerine, clonidine, estradiol (with and without norethisterone or levonorgestrel), 
testosterone, fentanyl, nicotine and lidocaine are the most important patch drugs.[14]  
Scopolamine patch was the first transdermal patch to reach the market and allowed 
the treatment of motion sickness. Until here, scopolamine had a short elimination half-time, 
expecting a short action duration. The finding of great scopolamine flux through human skin 
lead the development of a transdermal patch. In 1979, a patch with 2.5 cm2 was incorporated 
with 1.5 mg of scopolamine, being until now the smallest patch on the market (Transderm 
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Scop®; Novartis Consumer Health). This patch not only provided significant effect against 
motion sickness but also showed few side effects.[110,111] 
Until the marketing of the transdermal scopolamine patch, a nitroglycerin ointment was 
the only transdermal product in the market. Nitroglycerin is common used for angina 
pectoris and the ointment required frequent dosage. In 1981, nitroglycerin transdermal 
patches with different structures and dosages were introduced in the market, exhibiting 
treatment durability up to 12 h. Some years later, the addition of ethanol as a permeation 
enhancer increased the drug flux, turning this device into the most commercially consumed 
nitroglycerin patch throughout the market .[110,112]  
Another example is clonidine, an efficient drug to hypertension. Transdermal clonidine 
was developed to reduce drug side effects of the previous treatments and improve patient 
compliance. In 1980, the first transdermal patch to hypertension therapy was developed and 
clonidine was the elected drug. The system contained a polyisobutene–clonidine reservoir 
and contact adhesive layer with a microporous membrane in-between that controlled the 
drug release rate. However, adverse reactions were observed leading to treatment 
discontinuation.[110,113] 
One of the drugs that led higher number of patches was oestradiol. This drug is frequently 
used for post-menopausal replacement therapy and was first applied as a gel. This dosage 
form was messy and had difficult dosage control, which promoted the development of a 
transdermal patch in 1983. Oestradiol was administrated within a vehicle rich in ethanol, 
used as percutaneous absorption enhancer. In 1984 the patch reached the market with 
sufficient drug plasma level to meet the early follicular phase hormone levels. The new 
device allowed a reduction in the required daily dose, contributing to less side effects.[110,114] 
The Alza fentanyl patch, marketed by Johnson & Johnson (J&J) as Duragesic®, has 
dominated the transdermal market with peak sales greater than $2 billion in 2004. As 
fentanyl is applied to pain treatment, long-term release is a major demand. In fact, fentanyl 
patch showed a drug release for at least 12 h and for up to 7 days. The patch ran into 
difficulties in 2006 with patent expiration and further studies revealed the likelihood of 
fentanyl leakage out the patch reservoir. As result of J&J’s assertive marketing and patent 
protection, J&J patch sales surpassed $1.2 billion in 2006 and $900 million in 2009.[110,115] 
Nicotine is another example of drug patches with commercial success with total sales 
approaching US $1 billion during their year of introduction. Over a million smokers gave up 
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smoking with the help of nicotine patches. One of this first systems consisted in an occlusive 
transdermal pad designed to be attached to the skin with a reservoir liquid nicotine base. The 
drug delivery was controlled with a microporous membrane with a duration of 30–45 min, 
thus requiring the application of several patches along the day. A subsequent patent disclosed 
a monolithic patch with a polyurethane matrix layer. This system solved the problem with 
nicotine delivery through skin over at least 24 h.[110,116] 
Testosterone is another widely-used drug in commercial available transdermal patches 
to treat hypogonadism. Originally, testosterone was applied as a cream but skin-to-skin 
transfer of testosterone gel from parents to their young children or from males to their female 
sexual partners were testified, resulting in precocious puberty or pronounced virilisation. To 
avoid this, testosterone patches were designed to be applied to the highly permeable scrotal 
tissue. However, high serum testosterone levels after scrotal application were observed, 
which can be associated to detrimental effects on the prostate. A non-scrotal skin application 
overcame these difficulties.[110,117] 
 
Table 2.3. Commercially available transdermal patches approved by the US FDA. Adapted from Pastore and 
colleagues-[110] 
Drug Trade name (year) Indication 
Patch 
design 
Dose and patch 
size 
Duration  
Buprenorphine Butrans®(2010) Chronic pain DIA 5 mg in 6.25 cm2 7 days 
Clonidine 
Catapres-
TTS®(1984) 
Hypertension Reservoir 2.5 mg in 3.5 cm2 7 days 
Oestradiol 
Estraderm®(1986) 
Female 
hormone 
replacement 
therapy 
(HRT) 
Reservoir  24 mg in 10 cm2 3-4 days 
Climara®(1994) 
DIA 
2 mg in 6.5 cm2 7 days  
Vivelle®(1994) 4.33 mg in 14.5 cm2 3-4 days 
Alora®(1996) 0.77 mg in 9 cm2 3-4 days 
Vivelle-Dot®(1999) 0.39 mg in 2.5 cm2 3-4 days 
Menostar®(2004) 1 mg in 3.25 cm2 7 days 
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Minivelle®(2012) 0.62 mg in 2.48 cm2 3-4 days 
Evamist®(2007) 
Cutaneous 
solution 
1.53 mg per spray 
(90 µl) 
One 
spray/ day 
Oestradiol/Noret
hindrone 
Combiptach®(1998) Female HRT DIA 
0.62 mg/2.7mg in 9 
cm2 
3-4 days 
Ethinyl 
oestradiol/ 
Norethindrone 
Ortho Evra®(2001) 
Female 
contraception 
DIA 
0.75 mg/6mg in 20 
cm2 
7 days 
Oestradiol/Levon
orgestrel 
Climara Pro®(2003) Female HRT DIA 
4.40mg/1.39mg in 
22 cm2 
7 days 
Fentanyl Duragesic®(1990) Chronic Pain DIA 2.1 mg in 5.25 cm2 72 h 
Granisetron Sancusi®(2008) Chemotherapy DIA 34.3 mg in 52 cm2 
Up to 7 
days 
Methylphenidate Daytrana®(2006) ADHD1 DIA 27.5 mg in 12.5 cm2 Up to 9 h 
Nitroglycerin 
Nitro-Dur®(1995) 
Angina 
pectoris 
DIA 
20 mg in 5cm2 
12-14 h 
Minitran®(1996) 9 mg in 3.3 cm2 
Oxybutynin Oxytrol®(2003) 
Overactive 
bladder 
DIA 36 mg in 39 cm2 3-4 days 
Rivastigmine Exelon®(2007) 
Alzheimer’s 
Parkinson’s 
Matrix 9mg in 5 cm2 24 h 
Rotigtine Neupro®(2007) 
Parkinson’s 
Restless legs 
syndrome 
DIA 2.25 mg in 5 cm2 24 h 
Scopolamine Transderm®(1981) 
Motion 
sickness 
DIA 1.5 mg in 2.5 cm2 72 h 
Selegiline Emsm®(2006) 
Depressive 
disorder 
Reservoir 20 mg in 20 cm2 24 h 
Testosterone 
Androderm® (1995) 
Hypogonadis
m 
Reservoir 9.7 mg in 32 cm2 24 h 
Axiron®(2010) 
Cutaneous 
solution 
30 mg per pump 
actuation 
2 pump 
actions 
per day 
Nicotine 
Habitrol®(1990) 
Smoking 
cessation 
Matrix 17.5 mg in 10 cm2 24 h 
Nicoderm®(1991) Reservoir 36 mg in 7 cm2 24 h 
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Nicorette® Matrix 8.3 mg in 10 cm2 16 h 
Nicorette® Matrix 15.75 mg in 9 cm2 16 h 
Sumatripan Zecuity®(2013) Migraine 
Iontophoreti
c system 
36 mg in 7 cm2 4 h 
Capsaicin Qutenza®(2009) 
Neuropathic 
pain 
DIA 179 mg in 280 cm2 
60 min of 
up to 4 
patches 
Diclofenac 
epolamine 
Flector®(2007) Acute pain DIA 180 mg in 140 cm2 12 h 
Lidocaine Lidoderm®(1999) 
Post-herpetic 
neuralgia pain 
DIA 700 mg in 140 cm2 
Only once 
for up to 
12h 
Lidocaine/Tetrac
aine 
Synera®(2005) 
Local 
analgesia 
Eutetic 
mixture-
CHADD® 
70 mg/70mg in 50 
cm2 
20-30 min 
Menthol/Methys
alicylate 
Salonpas®(2008) 
Muscles and 
joints pain 
DIA 3%/10% in 70 cm2 
Up to 8-
12 h 
1 Attention deficit hyperactivity disorder (ADHD) 
10. Clinical Trials 
Currently there are 2060 ongoing clinical trials regarding the use of patches for skin 
disorders. Still, only 7 represent systems of higher complexity composed of patches with 
drug particles embedded. Such arrangements are expected to exhibit enhanced performance 
concerning the storage and consequent release of drug.[94,118] Table 2.4 displays the main 
information with regards to these ongoing clinical trials. Bio-medical Carbon Technology 
(BCT), an antimicrobial dressing invented by Bio-medical Carbon Technology Co., Ltd., 
particularly consists of activated carbon fibers impregnated with silver particles. One of the 
clinical trials is based on the investigation of wound healing effects of BCT antimicrobial 
dressing on deep dermal burn.[119] BCT silver bandage is also evaluated in another clinical 
trial to achieve its efficacy and safety in obstetrical and gynecological surgical wound 
healing, being compared to Aquacel® Ag, a commercial dressing.[120] TulleGras M.S 
(vaseline gauze) and Urgotul (low-adherent dressing) have been experienced on surgical 
acute wounds, demonstrated both suitable healing rates as well as painless dressing 
removal.[121] HIV infection is a condition that promoted the development of 3 of the 7 
ongoing clinical trials. DermaVir is a synthetic nanomedicine whose active ingredient is a 
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single plasmid DNA expressing 15 HIV proteins that assemble to HIV-like particles. 
DermaVir is topically administered to target the nanomedicine to Langerhans cells. These 
cells migrate to the lymph nodes to induce cytotoxic T- cells that can kill HIV-infected cells. 
This patch is applied in all ongoing clinical trials related to HIV infection. Safety, 
tolerability, immunogenicity, and preliminary antiretroviral activity are the main parameters 
under investigation in these studies.[122–124] 
Table 2.4. Clinical trials using patches with drug particles for a wide variety of disorders/diseases. 
N.A. – not available 
An estrogen patch in another example involved in a trial. The postmenopausal state 
is associated with increased risk of heart diseases due to the loss of estrogen and this 
subsequent effect in lipids loss. This condition is often treated by estrogen replacement 
Clinical Trial Condition Drug/ Device Sponsor Phase Status 
To Study the Healing Effect of 
Silver Impregnated Activated 
Carbon Fiber Wound Dressing 
on Deep Dermal Burn 
(clinicaltrials.gov2014) 
Burns 
Activated carbon 
fiber impregnated 
with silver 
particles 
Bio-medical 
Carbon 
Technology 
Co., Ltd. 
N.A. Completed 
Comparison of Efficacy on 
Healing, and Safety of Two 
Dressings Urgotul and 
TulleGras MS on Surgical 
Acute Wounds 
(clinicaltrials.gov2016) 
Surgical Acute 
Wounds 
Urgotul: Low-
adherent dressing 
and TulleGras 
M.S.: Vaseline 
gauze 
Mylan Inc. Phase 4 Completed 
A Comparative Efficacy and 
Safety Study Between Two 
Silver Containing Dressings In 
Post-Op Wound Healing 
(clinicaltrials.gov2014) 
Surgical 
Wound 
BCT Silver 
Bandage and 
Aquacel® Ag. 
Dressing 
Bio-medical 
Carbon 
Technology 
Co., Ltd. 
N.A Terminated 
Antiretroviral-Sparing 
Concept With HIV-specific T 
Cell Precursors With High 
Proliferative Capacity (PHPC) 
(PHPC-02) 
(clinicaltrials.gov2013) 
HIV Infection DermaVir  
Genetic 
Immunity 
Phase 2 Completed 
Single DermaVir 
Immunization in HIV-1 
Infected Patients on HAART 
(GIHU004) 
(clinicaltrials.gov2013) 
HIV Infection DermaVir  
Genetic 
Immunity 
Phase 1 Completed 
Repeated DermaVir 
Immunizations in HIV-1 
Infected Treatment-naïve 
Patients (GIEU006) 
(clinicaltrials.gov2013) 
HIV Infection DermaVir 
Genetic 
Immunity 
Phase 2 
Active, not 
recruiting 
Midlife Cholesterol Study 
(clinicaltrials.gov2014) 
Menopause 
Postmenopause 
Premenopause 
Cardiovascular 
Disease 
Tansdermal 
estradiol patch 
Northwester 
University 
Phase 4 Completed 
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therapy, having a beneficial effect on lipid levels. The purpose of this research study is to 
understand how menopause affects lipids and how hormone replacement therapy effects the 
lipid metabolism of postmenopausal women. A transdermal estradiol patch is here applied 
to estrogen replacement.[125] 
11. Final Remarks 
The development of new and effective DDS has been greatly improving treatments 
efficacy, solving problems commonly associated with the use of conventional “free” drugs. 
Their administration through transdermal route has been attracting considerable attention 
due to its numerous advantages, such as less frequent, painless and flexible dosing, as it also 
generates less amount of dangerous waste. These factors have been stimulating the research 
and development of transdermal DDS to effective deliver therapeutic molecules to skin 
targets.  
Patches are the most common used transdermal DDS, mostly due to their simple design, 
application and low production cost. In order to solve the limitations associated with these 
passive transdermal DDS, higher drug concentration must be applied to improve 
transcutaneous fluxes. Biodegradable or non-biodegradable polymers have been exploited 
to engineer robust devices able to deliver accurate amounts of drugs during a prolonged 
period of time with minimal side effects by different types of patches. The combination of 
drug particles with patches also enables the development of more efficient systems. Both 
drug permeation and drug flux across the skin membranes are increased through particle size 
diminution to micro and nano scales, increasing their bioavailability, surface area and 
solubility.  
Even though different types of patches have been engineered for the last five decades, 
there is still a need for the development of systems able to retain and release high amounts 
of drug in a sustained or controlled form. These devices are of major importance in order to 
deliver specific amounts of drugs in prolonged treatments of particular diseases. We 
hypothesise that more efforts should be made in the development of patches incorporating 
micro and/or nanoparticles and/or fabrication of drug carries. From all the aforementioned 
patches, non-biodegradable ones are able to incorporate larger amount of drugs, being a 
potential solution to treat cutaneous wounds needing prolonged treatments. Polymeric 
patches showed to solve hydrogels limitations, being easy to handle with higher mechanical 
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resistance and great storage over the time. However, when compared to hydrogels, lower 
drug permeation was achieved, especially with hydrophilic drug molecules or with higher 
molecular weight (> 500Da).  
Although major achievements have been attained in the development of more 
sophiscated patches, some limitations still need to be overcome. Particularly, 
physicochemical properties of drug continue to play an important role in its transport through 
the skin layers and low transcutaneous flux, drug incorporation and retention in the patch 
still limited their application. 
Further research should be developed in order to attain a patches with ideal features from 
the simplest to most complex hierarchical patches with stimuli- and multiple-release of a 
large pool of drugs. 
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Chapter 3 - Materials and Methods 
1. Materials 
All chemicals were purchased from Sigma-Aldrich unless otherwise specified and 
were used as received. Polydimethylsiloxane (PDMS) - SYLGARD® 184 SILICONE 
ELASTOMER KIT was purchased by Dow corning and silicon micromolds were designed 
and fabricated at CENIMAT at NOVA, New University of Lisbon. 
2. Methods  
2.1.Micropatterned patch fabrication 
 
PDMS micropatterned patch (PMP) were obtained by solving casting process 
technique, as described previously.[1] Briefly, different silicon wafers were used as masters 
to obtain PMP (1.44 cm2) with different distances between the micropillars (40, 80, and 160 
µm) and heights (100, 300, and 550 µm). In order to reduce PMP-silicon molds adhesion, 
silicon molds were treated with a silanization protocol. Silicon molds were cleaned with 
isopropanol and dried in N2. After being treated with vacuum air plasma for 3-4 min, the 
master was placed into a vacuum desiccator along with a small beaker containing a few drops 
( 20µL/mold) of trichloro(1H,1H,2H,2H-perfluorooctyl)silane for 2 h.[2] Additionally, 
PMP with variable flexibilities were prepared by using variable base:curing agent ratios, 
namely 5:1, 10:1, and 15:1. The mixture was then degassed in a vacuum desiccator in order 
to remove all air bubbles and then poured onto the silicon mold. The molds were cured at 
70C for 2 h.[3] PMP were also produced by double casting process using PDMS master. For 
easier manipulation purposes and to preserve silicon master molds integrity, the previously 
fabricated negative PMP were used as masters to positive PMP fabrication, enabling the 
production of the massive number of negative replicas needed to conduct this study. Same 
procedure with some modifications was used. PMP were treated with vacuum air plasma for 
10 minutes, the master was placed into a vacuum desiccator along with a small beaker 
containing a few drops ( 20µL/mold) of trichloro(1H,1H,2H,2H-perfluorooctyl)silane for 
40 min.  
PDMS residues were removed from silicon molds as described in literature [4]. A 
dilute solution of TBAF (1% w/v) in hydrophobic non-hydroxylic aprotic solvent (PMA) 
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was used to remove the PDMS residues. The solution containing TBAF caused rapid 
disruption/disintegration of PDMS polymer matrix and removed it by dislodging it from the 
surface and, to a large extent, by dissolution of the PDMS residues. A key feature of the 
chemistry used herein is the compatibility of etchant with the flexible PI substrate. The 
sample was immersed in the solution which was stirred continuously. The solution was 
maintained at a temperature of 50 C throughout the cleaning process as this temperature 
results in faster etching. The cleaning action was performed for a period depending on the 
amount of polymer residues. An etching rate of 1–1.5 mL/min was showed. After the first 
etching step, the sample was transported to the first solvent rinse bath comprising of 
preheated (50 C) PMA solvent. 
 
2.2. Production of PCL microparticles  
In order to prove the previously presented concept a set of PCL microparticles were 
produced by microfluidics device with different diameters (40, 80 and 160 µm) to test the 
different responses by the PMP. The different diameters were obtained based on the variation 
of flow rate and the concentration of the PLC solution. The surfactant that was used in this 
process was a diluted solution of PVA 2% (w/v). PLC solution was prepared in DCM and 
PVA in distilled water. The conditions are described in the following table.  
Table 3.1. Parameters to PLC microparticles production. 
Particle Size 
(µm) 
PVA concentration 
(%) 
Flow rate 
PVA (mbar) 
PLC concentration 
(%) 
Flow rate 
PCL (mbar) 
40 2.0 300 5.0 270 
Microfluidic techniques are widely applied in microparticles preparation. Through 
this method, various shapes and morphologies polymer particles can be obtained.[5] 
Microfluidcs device was the first trial and was used a chip in “T form” (Figure 4A), where 
PCL microparticles were formed by the combination of a discontinuous flow of polymer 
solution (PCL) with a continuous flow of surfactant (PVA). According to Table 3.1, the 
particle size was very similar. Figure 3.1 presents the size distribution of PCL microparticles 
that showed low polydispersity (26.5± 5.4 µm) with a very stable system. Lin and co-workers 
produced PCL microparticles with a microfluidic device and similar results were obtained. 
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PCL microparticles showed consistent morphology (sphericity and smooth surface) and 
excellent size uniformity.[6] 
Due to the high number of combinations tested (three different micropillars spacing, 
microparticles diameters, micropillars height and patch flexibility, N= 3), considerable 
number of microparticles were needed. Therefore, although microfluidics achieved 
monodispersed microparticles, another process was to be found due the time required in 
production of microparticles with microfluidics. Being a faster, reproducible and precise 
methodology, emulsion technique was used to engineer PCL microparticles. For the purpose, 
a 4.5 % (w/v) PCL solution was prepared in DCM and 0.5 % (w/v) PVA solution was 
prepared in distilled water. PCL solution (8 mL) was added with OB1 Pressure Controllor 
(Elveflow, France) to PVA solution (150 mL) in continuous stirring at 800 rpm.[7] 
Microarticles were dried at 170 rpm in microplate agitator and then washed twice against 
distilled water under centrifugation at 1000 rpm for 5 min. Microparticles with different 
diameter ranges, namely [25-40]µm, [63-80]µm, and [100-160]µm, where selected with the 
aid of sieves. At the end, the sieves were washing in ultrasonic bath and dried with 
compressed air. 
To allow a better visualization of the entrapment of microparticles within PMP, 
comarin-6 was dissolved in acetone (2 mg/mL) and added to the PCL solution. To each 8 
mL of PCL 70 µL of comarin-6 solution was used. Comarin-PCL microparticles were 
produced following the same protocol described for PCL microparticles. 
2.3.Production of tetracycline-loaded alginate microparticles  
Alginate microparticles were produced by electrospraying technique (SprayBase, 
Avectas, Ireland). First, microparticles with and without tetracycline were optimized in order 
Figure 3.1. Production of PCL microparticles by microfluidics A. Microfluidics device B. Microscope 
image of PCL microparticles (10x) obtained by microfluidic device C.  Particle size distribution of PCL 
microparticles obtained by microfluidics. 
CHAPTER 3  MATERIALS AND METHODS 
 
50 
 
to obtain a rounded shape and a diameter of 80 µm. Parameters were set as: flow rate 1.0 
m/h, voltage 15 kV, and needle-to-collector distance 6 cm. To optimize the encapsulation of 
tetracycline, two different methodologies were performed. For unloaded microparticles a 
needle diameter of 22G was used with an alginate concentration of 2.0 % w/v. For 
tetracycline-loaded microparticles the needle diameter and the polymer concentration were 
decreased to 26G and 1.75 % w/v, respectively. Calcium chloride (0.1M) was used as the 
crosslinking bath under continuous agitation (300 rpm). In a subsequent experiment, alginate 
microparticles obtained by electrospray technique (10 mg) were lyophilized and then 
suspended in 5 mL of tetracycline solution. The suspension was allowed to stir at room 
temperature (RT) during 24h and then again lyophilized.[8,9] The amount of tetracycline 
encapsulated was determined by decrosslinking the alginate microparticles in 
ethylenediaminetetraacetic acid (EDTA, 0.1M) solution. Absorbance was read at 362 nm in 
a microplate reader (Synergy HTX, BioTek Intruments, USA) using a corning 384 quartz 
microplate (Hellma). Drug content and drug entrapment were calculated according to the 
following equations: 
𝐷𝑟𝑢𝑔 𝑐𝑜𝑛𝑡𝑒𝑛𝑡 (% 𝑤/𝑤) =  
𝑚𝑎𝑠𝑠 𝑜𝑓 𝑑𝑟𝑢𝑔 𝑖𝑛 𝑚𝑖𝑐𝑟𝑜𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒𝑠
𝑚𝑚𝑖𝑐𝑟𝑜𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒𝑠
× 100 
Equation 1 
𝐷𝑟𝑢𝑔 𝑒𝑛𝑡𝑟𝑎𝑝𝑚𝑒𝑛𝑡 (% 𝑤/𝑤) =  
𝑚𝑎𝑠𝑠 𝑜𝑓 𝑑𝑟𝑢𝑔 𝑖𝑛 𝑚𝑖𝑐𝑟𝑜𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒𝑠
𝑚𝑎𝑠𝑠 𝑜𝑓 𝑑𝑟𝑢𝑔 𝑢𝑠𝑒𝑑 𝑖𝑛 𝑓𝑜𝑟𝑚𝑢𝑙𝑎𝑡𝑖𝑜𝑛
× 100 
Equation 2 
2.4.Microparticles incorporation into PMP 
The different PMP were pressed against the produced microparticles in order to 
promote their capture. Different combinations of particle size and distance between the 
pillars were obtained (Table 3.2). As previously mentioned, 3 different PDMS rigidity and 
pillars height were also used. To evaluate the entrapment efficiency, the different 
formulations of PMP entrapping different microparticles were weighted. 
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Table 3.2. Different formulations of PMP entrapped with different microparticles.  
 Microparticle size (µm) 
Micropillars spacing (µm) 40 80 160 
40 x x x 
80 x x x 
160 x x x 
 
Microparticles adherence to different PMP were also investigated through different 
techniques: fluorescence microscopy and SEM. 
Entrapment efficiency was determinate by following equation:  
𝐸𝑛𝑡𝑟𝑎𝑝𝑚𝑒𝑛𝑡 𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑐𝑦 (𝑚𝑔/𝑐𝑚2)  =
𝑚𝑎𝑠𝑠 𝑜𝑓 𝑚𝑖𝑐𝑟𝑜𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒𝑠
𝑎𝑣𝑎𝑖𝑎𝑏𝑙𝑒 𝑎𝑟𝑒𝑎
 
Equation 3 
Each PMP have a total area of 1.44 cm2. The available area represents the space 
between the micropillars (similar to cylinders) and was defined by: 
𝐴𝑣𝑎𝑖𝑎𝑏𝑙𝑒 𝑎𝑟𝑒𝑎 =  𝑡𝑜𝑡𝑎𝑙 𝑎𝑟𝑒𝑎 − 𝑚𝑖𝑐𝑟𝑜𝑝𝑖𝑙𝑙𝑎𝑟𝑠 𝑎𝑟𝑒𝑎 × 𝑚𝑖𝑐𝑟𝑜𝑝𝑖𝑙𝑙𝑎𝑟𝑠 𝑛𝑢𝑚𝑏𝑒𝑟 
Equation 4 
𝑚𝑖𝑐𝑟𝑜𝑝𝑖𝑙𝑙𝑎𝑟𝑠 𝑎𝑟𝑒𝑎 = 2𝜋𝑟 × 𝑚𝑖𝑐𝑟𝑜𝑝𝑖𝑙𝑙𝑎𝑟𝑠 ℎ𝑒𝑖𝑔𝑡ℎ 
Equation 5 
Considering that pillars diameter of 60 µm, pillars number was achieved by:  
𝑚𝑖𝑐𝑟𝑜𝑝𝑖𝑙𝑙𝑎𝑟𝑠 𝑛𝑢𝑚𝑏𝑒𝑟 =  
𝑡𝑜𝑡𝑎𝑙 𝑎𝑟𝑒𝑎
 (60 + 60 + 𝑚𝑖𝑐𝑟𝑜𝑝𝑖𝑙𝑙𝑎𝑟𝑠 𝑠𝑝𝑎𝑐𝑖𝑛𝑔)2
 
Equation 6 
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2.5.Surfaces characterization 
The surface of PMP either with or without PCL microparticles was visualized by 
scanning electron microscopy (SEM, S4100, Hitachi, Japan). Silicon wafers were also 
visualized by SEM. The samples were gold-sputerred and operating at 25.0 kV accelerating 
voltage. PMP entrapping coumarin-PCL microparticles were visualized by EGFP 
fluorescence microscopy (Zeiss Imager M2, Zeiss, Germany).  
2.6.Mechanical Tests 
The mechanical behavior of the PMP was characterized through tensile test with 
Shimazdu MMT-101N (Shimazdu Scientific Instruments, Japan) a load cell of 100 N and a 
velocity of 1 mm·min-1. PMP and PMP with entrapped PCL microparticles were tested (three 
repeated simples). The sample thickness was measured using a micrometer with a precision 
of 1 μm. For each sample, the load versus cross-head displacement data from initial until 
rupture load were measured using a PC data acquisition system connected to the tester. The 
initial gauge length was set as 8 mm.[10] 
Young’s modulus (E) was calculated by dividing the tensile strength (σ) by the 
extensional strain (ε) in the linear (elastic) portion of the physical stress–strain curve, as 
described in the following equations: 
𝑌𝑜𝑢𝑛𝑔′𝑠 𝑚𝑜𝑑𝑢𝑙𝑢𝑠 (𝑃𝑎) =  
𝜎 (𝜀)
𝜀
 
Equation 7 
  Elongation factor (ε, adimensional) was obtained by the division between 
elongations at each point by the gange length (original length of the object). 
𝐸𝑥𝑡𝑒𝑛𝑠𝑖𝑜𝑛𝑎𝑙 𝑠𝑡𝑟𝑎𝑖𝑛 (𝜀) =
𝜀(𝑡)
𝐺𝑎𝑛𝑔𝑒 𝑙𝑒𝑛𝑔𝑡ℎ 
 
Equation 8 
 Tensile strength (σ, Pa), force exerted on the object, was calculated through the 
division of the exerted force at each point by the cross-sectional area (width × thickness). 
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𝑇𝑒𝑛𝑠𝑖𝑙𝑒 𝑠𝑡𝑟𝑒𝑛𝑔𝑡ℎ (𝜎) =  
𝑒𝑥𝑒𝑟𝑡𝑒𝑑 𝑓𝑜𝑟𝑐𝑒 (𝑡)
𝑤𝑖𝑑𝑡ℎ × 𝑡ℎ𝑖𝑐𝑘𝑒𝑛𝑠𝑠
 
Equation 9 
2.7.Release Assay 
 
The optimized system previously described as PMP with 80:80:300m 
(microparticle diameter:micropillar spacing:micropillar height) with 10:1 flexibility was 
tested for controlled released studies under sink conditions. For this, a model antibiotic 
(tetracycline hydrochloride) was used, and was monitored through UV-vis spectroscopy at 
362 nm. The release assays were performed in phosphate-buffered saline (PBS) solutions at 
physiological pH (7.4) and wounds pH (5.5). The drug release content from PMP with 
tetracycline-loaded alginate microparticles or tetracycline-powder microparticles was 
evaluated. Non-loaded alginate microparticles, and PMP without entrapped microparticles 
were used as controls. Briefly, the samples were immersed in 5 mL of PBS and subsequently 
stirred in a shaking water bath at 60 rpm and 37ºC. At predetermined time intervals, aliquots 
of 500 µL of PBS were withdrawn and the same volume of fresh buffer solution was 
added.[11] UV-spectroscopy was measured at 362 nm in a microplate reader (Synergy HTX, 
BioTek Intruments, USA) using a corning 384 quartz microplate (Hellma).  
 
𝐴𝑐𝑢𝑚𝑢𝑙𝑎𝑡𝑖𝑣𝑒 𝑡𝑒𝑡𝑟𝑎𝑐𝑦𝑐𝑙𝑖𝑛𝑒 𝑟𝑒𝑙𝑒𝑎𝑠𝑒 (%) =
𝑉𝑒 ∑ 𝑐𝑖 + 𝑉0𝑐𝑛
𝑛−1
𝑖
𝑚𝑑𝑟𝑢𝑔
× 100 
Equation 10 
2.8.Growth inibihition assay 
The ability of PMP (6 mm diameter) entrapped with tetracycline-loaded alginate 
microparticles and tetracycline powder microparticles to inhibited bacterial growth was 
investigated using Escherichia coli (ATCC) and Staphylococcus aureus (ATCC) culture. 
PMP without alginate microparticles entrapped or loaded with alginate microparticles 
without tetracycline were used as controls. Colonies isolated from nutrient agar were 
inoculated to 5 mL Lysogeny broth (LB) medium (Merck) and incubated for 18–24 h in a 
shaking water bath at 180 rpm and 37ºC. The obtained cellular suspensions (1 mL) were 
centrifuged (13000g, 10 min). Pellet suspensions were then prepared in sodium chloride 
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(NaCl) solution (0.9% w/v). The cellular density was determinate by UV-vis spectrometry 
at 600 nm (UV mini-1240 UV-VIS Spectrophotometer, Shimadzu). After inoculum 
spreading in Muller Hinton agar medium (nzytech), samples were placed and incubated at 
37°C for 24 h.[12] At the end, diameters of inhibition zones around the constructs were 
measured manually. Each disc diffusion test was repeated three times.  
2.9.Statistics  
All statistical analysis were perfomed in GraphPad using two-way ANOVA analyses 
of variance following the Bonferroni post-hoc test with a significant set at p < 0.05. 
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Abstract 
Biomimetic systems exhibit often striking designs well adapted to specific 
functions that have inspired scientists and engineers in the development of new 
technologies and processes. In this work we explore the remarkable ability of honey bees 
to catch and release large amount of grains pollen during pollination. We believe that the 
hair spacing and height on bees‘ foreleg is relevant for leg’s ability to mechanically fix 
microsized grains pollen. Inspired by this observation we propose the concept of a novel 
micropatterned surface featuring spaced high aspect-ratio micropillars to mimic the hair 
of bee’s legs for microparticles entrapment. The hypothesis was validated by 
investigating the ability of bioinspired polydimethylsiloxane microfabricated patches to 
fix microparticles. Different conditions were tested, namely the geometry arrangement, 
spacing, height, and flexibility of micropillars combined with microparticles with variable 
diameters. Our results are consistent with the observations that the diameter of grain 
pollens is similar to the distance between the legs’ hair. Our biomimetic surfaces were 
explored for the fixation of solid microparticles for drug release applications, using 
tetracycline hydrochloride as a model antibiotic. We investigated patches entrapping (i) 
tetracycline hydrochloride powder or (ii) tetracycline-loaded alginate microparticles. 
While tetracycline powder is immediately released, the tetracycline-loaded alginate 
microparticles allow a controlled and sustained release of the active pharmaceutical 
ingredient during 5 days with a maximum cumulative release of 81.6 ± 3.8 %, also 
exhibiting an antimicrobial activity. Such bioinspired hairy surfaces could find 
applications in other fields where universal dry fixation of high-quantity of micro-objects 
are needed, including in agriculture (fixation of seeds or solid fertilizers), 
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biotechnology/chemical industry (e.g. immobilization of microorganisms and in 
heterogeneous catalysis) and in the new conception of cleaning utensils. 
Key words: Biomimetic, drug carries, honey bee, micropatterning, patches, 
pollination, transdermal drug delivery. 
1. Introduction 
In nature, biological organisms exhibiting unique features have been a source of 
inspiration to the development of high performance structures and biomaterials. 
Commonly found in nature, different hierarchical structures range across macroscale to 
the nanoscale and could lead to promising applications.[1] The emerging field of 
biomimetics allowed the fabrication of novel soft materials and functional surfaces based 
on the understanding of nature designs and processes in order to solve current problems 
in engineering, materials science and biomedicine.[2,3] 
Superhydrophobicity, self-cleaning, drag reduction in fluid flow, high and 
reversible adhesion, aerodynamic lift, high mechanical toughness, and self-healing are 
some of the numerous properties previously found in nature and employed in the 
development of news substrates and hydrogels.[2,4] For example, geckos, beetles, flies and 
other animals are some examples that have inspired the development of biomimetic 
adhesives due to their ability to reversibly adhere to surfaces. This capacity relies on the 
surface topography of their attachment pads,[5] which are covered with a pattern of 
microstructures, resembling the geometry of tenent hairs present in their feet.[6]  
In this work we are particularly interested on the peculiar hairy structure that 
covers the surface of the body, in particular the legs, of honey bees, able to carry millions 
of particles for pollination purposes (Figure 4.1A). Such insects have a typical branched 
hair with numerous short lateral barbs in-between pollen grains are entrapped. The hair 
covering the body allows the temporary retention of pollen, which is then removed by the 
combing action of the legs' brushes.[7–9] Thus, pollens and bees' hair legs are a naturally-
optimized system that can be used to inspire the development of substrates able to 
mechanically fix small solid objects which could find applicability in various 
fields(Figure 4.1B).  
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We propose the development of microfabricated substrates to reproduce this 
natural phenomenon, by exploring the microparticles’ fixation ability of micropatterned 
elastomeric films. We believe that such kind of substrates could be used in a wide variety 
of applications that require simple, non-permanent, high-content and pure-physical 
immobilization of solid particulate objects. We explore microparticles with variable 
diameters, combined with patches with different micropillars geometry arrangement, 
height, and spacing (Figure 4.1C). We finely demonstrated the usefulness of such 
concept in the development of a new generation of drug delivery patches. Current 
problems associated with passive delivery patches have been limiting their application,[10] 
and one valuable solution could be the application of higher drug content to improve 
transcutaneous fluxes and overcome their constraints.[11] Herein, we show the 
development of a hierarchical biomimetic patch consisting of a polydimethylsiloxane 
(PDMS) micropatterned structure with micropillars entrapped with polycaprolactone 
(PCL) microparticles or drug-loaded alginate microparticles. We envisage the possibility 
of having membranes with any desired shape and size that could immobilize any 
Figure 4.1. Schematic illustration of the development of the proposed biomimetic micropatterned structrure. 
A. The bees’ body is covered with hairs. Grains pollen are caught between the bees’ hair and their size is 
similar to the hair spacing; B. A bioinspired patch can be developed based on pollination by the construction 
of a micropatterning structure with micropillars with controlled spacing (s) and height (h). C. Capture of large 
amount of solid microparticles in micropillars spacing by direct contact and pressure; the entrapment efficiency 
will depend on the contrast between the pillars spacing (s) and the size of the microparticles.  
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combination of drug by simple direct contact with a powder formulation. As a proof-of-
concepct, tetracycline, a broad-sprectum antibiotic foreseen to act during the 
inflammatory phase of wounds, was used as active pharmaceutical ingredient (API). Such 
demonstration can extend the interest of such type of substrates able to entrap and fix 
solid micro-objects for other biomedical, agricultural, environmental and industrial 
applications.  
 
2. Materials and Methods 
 
2.1.Materials 
All chemicals were purchased from Sigma-Aldrich and used as received, unless 
otherwise specified. PDMS (Sylgard® 184 silicone elastomer kit) was purchased from 
Dow Corning. Silicon micromolds were designed and fabricated at CENIMAT at New 
University of Lisbon.  
2.2.Methods 
2.2.1. PDMS micropatterned patches fabrication 
PDMS micropatterning patches (PMP) were obtained by double casting process, 
as previously described.[12] Briefly, different silicon wafers were used as masters to obtain 
PMP (1.44 cm2) with different distances between the micropillars (40, 80, and 160 µm) 
and heights (100, 300, and 550 µm). Additionally, PMP with variable flexibilities were 
prepared by using variable base:curing agent ratios, namely 5:1, 10:1, and 15:1. The 
prepared PDMS solutions were then poured onto the silicon wafers, and cured at 70C 
for 2 h. To facilitate PMP-silicon detachment, silicon wafers were previously treated with 
a silanization protocol. Silicon wafers were cleaned with isopropanol and dried in 
nitrogen (N2) and after treated with Plasma System ATTTO (Aname, Spain)  for 3-4 min 
(30 V, 0.6 mbar), and immediately placed into a vacuum desiccator containing 
approximately 20µL/mold of trichloro(1H,1H,2H,2H-perfluorooctyl)silane for 2 h.[13] 
Same procedure was used to production of PMP using a PDMS master. 
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2.2.2. Production of microparticles  
 
2.2.2.1.PCL microparticles 
An emulsion technique was used to prepare the PCL microparticles.[14] PCL was 
dissolved in dichloromethane (DCM) (4.5% w/v) and dropwise to a stirring bath (800 
rpm) of polyvinyl alcohol (PVA) (0.5% w/v). OB1 Pressure Controllor (Elveflow, 
France) was used as the pumping system at 5000 mbar. After mild stirring to evaporate 
the organic solvent, the obtained microparticles were subsequently washed with distilled 
water, and collected by centrifugation (200g, 5 min). Microparticles with different 
diameter ranges, namely [25-40]µm, [63-80]µm, and [100-160]µm, where selected with 
the aid of sieves. To allow a better visualization of the entrapment of microparticles within 
PMP, comarin-6 was dissolved in acetone (2 mg/mL) and added to the PCL solution. To 
each 8 mL of PCL 70 µL of comarin-6 solution was used. Coumarin-PCL microparticles 
were produced following the same protocol described for PCL microparticles. 
 
2.2.2.2.Tetracycline-loaded alginate microparticles  
Alginate microparticles were produced by electrospraying technique (SprayBase, 
Avectas, Ireland). First, microparticles with and without tetracycline were optimized in 
order to obtain a rounded shape and a diameter of 80 µm. Parameters were set as: flow 
rate 1.0 ml/h, voltage 15 kV, and needle-to-collector distance 6 cm. To optimize the 
encapsulation of tetracycline, two different methodologies were performed. For unloaded 
microparticles a needle diameter of 22G was used with an alginate concentration of 2.0 
% w/v. For tetracycline-loaded microparticles the needle diameter and the polymer 
concentration were decreased to 26G and 2% w/v, respectively. Calcium chloride (0.1M) 
was used as the crosslinking bath under continuous agitation (300 rpm). In a subsequent 
experiment, alginate microparticles obtained by electrospray technique (10 mg) were 
lyophilized and then suspended in 5 mL of tetracycline solution. The suspension was 
allowed to stir at room temperature (RT) during 24h and then again lyophilized.[15]16] The 
amount of tetracycline encapsulated was determined by decrosslinking the alginate 
microparticles in ethylenediaminetetraacetic acid (EDTA, 0.1M) solution. Absorbance 
was read at 362 nm in a microplate reader (Synergy HTX, BioTek Intruments, USA) 
using a corning 384 quartz microplate (Hellma). 
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2.2.2.3.Tetracycline-powder microparticles 
Tetracycline-powder microparticles were obtained by milling tetracycline 
hydrochloride with the aid of a mortar with agate pestle. The obtained microparticles were 
then separated through diameter ranges of [25-40]µm, [63-80]µm, and [100-160]µm 
using sieves. 
2.2.3. Microparticles entrapment into PMP 
The different PMP were pressed against the produced PCL or alginate 
microparticles in order to promote their capture. To evaluate the entrapment efficiency, 
the different formulations of PMP entrapping different microparticles were weighted. 
2.2.4. PDMS micropatterned patches characterization 
The surface of PMP either with or without PCL microparticles was visualized by 
scanning electron microscopy (SEM, S4100, Hitachi, Japan). Silicon wafers were also 
visualized by SEM. The samples were gold-sputerred and operating at 25.0 kV 
accelerating voltage. PMP entrapping coumarin-PCL microparticles were accessed by 
EGFP fluorescence microscopy (Zeiss Imager M2, Zeiss, Germany).  
The mechanical behavior of different PMP was characterized through tensile test 
(MMT-101N, Shimazdu Scientific Instruments, Japan) with a load cell of 100 N and a 
velocity of 1 mm·min-1. PMP and PMP with entrapped PCL microparticles were tested 
(n=3). The sample thickness was measured using a micrometer with a precision of 1 μm. 
For each sample, the load versus cross-head displacement data from initial until rupture 
load was measured using a PC data acquisition system connected to the tester. The initial 
gauge length was set to 8 mm. 
2.2.5. In vitro release studies 
 
PMP with 80:80:300m (microparticle diameter:micropillar spacing:micropillar 
height) with 10:1 flexibility was tested for controlled released studies of tetracycline 
hydrochloride through UV-vis spectroscopy at 362 nm. The release assays were 
performed in phosphate-buffered saline (PBS) solutions at both physiological pH (7.4) 
and wounds pH (5.5). The drug release content from PMP with tetracycline-loaded 
alginate microparticles or tetracycline-powder microparticles was evaluated. Non-loaded 
alginate microparticles, and PMP without entrapped microparticles were used as controls. 
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Briefly, the samples were immersed in 5 mL of PBS and subsequently stirred in a shaking 
water bath at 60 rpm and 37ºC. At predetermined time intervals, aliquots of 500 µL of 
PBS were withdrawn and the same volume of fresh buffer solution was added. UV-
spectroscopy was measured at 362 nm in a microplate reader (Synergy HTX, BioTek 
Intruments, USA) using a corning 384 quartz microplate (Hellma). Drug release from 
swelling controlled systems (alginate microparticles) was modulated by the Kornsmeyer-
Peppas equation.[16–18] 
 
2.2.6. Growth inhibition assay 
The ability of PMP (6 mm diameter) entrapped with tetracycline-loaded alginate 
microparticles and tetracycline powder microparticles to inhibited bacterial growth was 
investigated using Escherichia coli (ATCC) and Staphylococcus aureus (ATCC) culture. 
PMP without alginate microparticles entrapped or loaded with alginate microparticles 
without tetracycline were used as controls. Colonies isolated from nutrient agar were 
inoculated to 5 mL Lysogeny broth (LB) medium (Merck) and incubated for 18–24 h in 
a shaking water bath at 180 rpm and 37ºC. The obtained cellular suspensions (1 mL) were 
centrifuged (13000g, 10 min). Pellet suspensions were then prepared in sodium chloride 
(NaCl) solution (0.9% w/v). The cellular density was determinate by UV-vis 
spectrometry at 600 nm (UV mini-1240 UV-VIS Spectrophotometer, Shimadzu). After 
inoculum spreading in Muller Hinton agar medium (nzytech), samples were placed and 
incubated at 37°C for 24 h.[19] At the end, diameters of inhibition zones around the 
constructs were measured manually. Each disc diffusion test was repeated three times.  
2.2.7. Statistics  
All statistical analysis were perform using GraphPad using two-way ANOVA 
analyses of variance following the Bonferroni post-hoc test with a significant set at 
p<0.05. 
3. Results  
3.1.Fabrication of PDMS micropatterned patches  
In order to achieve the most effective system, different constructs were fabricated 
to address their ability to catch and release spherical-shaped microparticles. PMP with 
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different flexibility were produced by varying the ratio between base and curing agent. 
For all the formulations investigated (5:1; 10:1; 15:1) the results, displayed in Figure S1 
(Supplementary Info), confirm that a higher base:curing agent ratio led to a higher 
flexibility of the mold. Different distances between the micropillars (40, 80 and 160 µm) 
and their height (100, 300 and 550 µm) were tested. PMP were prepared by cast molding 
technique, as briefly detailed in Figure 4.2A. The casting process consisted in pouring 
the pre-polymer of the elastomer over the master that was then cured and peeled off.[12] 
For easier manipulation purposes and to maintain silicon masters integrity negative 
PDMS molds were used to produce positive PDMS ones, that were later used to produce 
the massive number of negative replicas needed to conduct this investigation. Such 
negative PDMS replicas were used as substrate for the entrapment of microparticles, 
forming our biomimetic PMP.  
To investigate the accuracy of the molding step, samples were visualized by SEM. 
Micrographs displaying both negative and positive PMP molds can be depicted in Figure 
S2. Figure 4.2 also displays the silicon wafer used in this work and the obtained PMP 
with two different geometries herein used (square and hexagonal).  
Figure 4.2. Fabrication of PDMS micropatterning patches (PMP). A. Schematic illustration of the 
fabrication of microstructured PMP by cast molding following the production of PMP using both i.silicon 
master and ii. inverse PDMS mold as master; B. Macroscopic images of the silicion wafer used in this 
process (top photograph) and the obtained PMP with low thickness (bottom photographs); C. SEM images 
of obtained PMP with square and hexagonal distribution of the micropillars. Scale bars are 1 mm. 
Magnification is 30x. 
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3.2.Microparticle trapping assays 
In order to create an effective hierarchal patch comprising a flexible mold with 
maximum entrapment of microparticles, PCL microparticles were produced by emulsion 
technique (Figure S3A and B). Different sets of PCL microparticles with diameters 
matching the micropillars spacing, namely 40, 80, and 160 m, were selected. Although 
microparticles produced through emulsion technique are highly polydisperse with a 
coefficient of variance (cv) of 83.2% (25 ± 20.8 µm), as demonstrated in Figure S3C, the 
sieving methodology enables to significantly decrease the cv to 15.8%, and thus obtain a 
monodisperse population of microparticles.  
To achieve the most efficient system for microparticles trapping, different 
combinations of microparticles diameter, PMP flexibility, and micropillars spacing and 
height were investigated. A total amount of 243 combinations were tested. For the sake 
of simplicity, the differently spaced PMP and microparticles combinations will be 
numerically represented as microparticle:micropillar spacing. According to Figure 4.1, 
and more recent reports in the literature, pollen size appears to be very similar to the 
distance between the bees’ foreleg hair, enabling a maximized accommodation of grain 
pollens.[7] By creating a system inspired in this organized process, it is hypothesized that 
the proposed biomimetic patch will be able to capture more efficiently microparticles 
with sizes matching the distance between the micropillars, afterwards allowing 
microparticles release, and consequently their content, in a sustained or controlled 
fashion.  
3.2.1. Micropillars spacing  
Based on Figures 4.3A-C, the entrapment efficiency is higher when the 
micropillars spacing and the diameter of microparticles are similar, regardless the height 
of the micropillars. Consequently, as the difference between the diameter of 
microparticles and micropillars spacing increases, the entrapment efficiency decreases. 
For instance, for a PMP with 300 m of height entrapping microparticles with 40µm of 
diameter (Figure 4.3A), the entrapment efficiency decreased from 14.0 ± 0.1 (40:40) to 
12.1± 0.1 (80:40) mg/cm2 as the spacing of the micropillars increased (p < 0.01**).  
Consequently, increasing such difference by entrapping 40 µm microparticles within 
PMP with 160 µm micropillars spacing (40:160), resulted in a higher significant 
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difference (p < 0.0001****) in the entrapment efficiency, which presented the lowest 
values of 8.3 ± 0.4 mg/cm2. A similar trend was found for 80 m microparticles (Figure 
4.3B). For instance, again for a PMP with 300 m of height, the entrapment efficiency 
significantly decreased from 24.8 ± 0.4 (80:80) to 19.1 ± 0.3 mg/cm2 (80:160) (p < 
0.0001****) when the micropillars spacing increased from 80 µm to 160 µm. SEM 
micrographs (Figure 4.3D) corroborate these findings and also demonstrate that when 
microparticle size was smaller than micropillars spacing, ones were only superficially 
attached to the microstructures leaving the space between the micropillars empty. 
Micropillars roughness, displayed on Figure S7, may explain such microparticles’ 
adhesion. On the other hand, when the diameter of microparticles was higher than 
micropillars spacing, microparticles were not able to fit in the space between. However, 
micropillars showed some flexibility and were able to bend, enabling a limited 
microparticle’s trapping. For instance, when 80 µm microparticles were combined with 
40 µm spaced PMP (80:40), micropillars bent to accommodate a maximum amount of 
microparticles and, although the PMP remained mostly filled, there was a significant 
reduction of the entrapment efficiency from 24.8 ± 0.4 (80:80) to 19.5 ± 0.3 mg/cm2 (p < 
0.0001****). The same behaviour was evidenced upon the combination of larger 
microparticles with the same type of PMP (160:40) where the entrapment efficiency 
suffers a significant decreased from 29.4 ± 1.0 (160:160) to 13.1 ± 0.5 mg/cm2 (p < 
0.0001****). Similar result was obtained when such larger microparticles were trapped 
within the 80 µm spaced PMP (160:80) showing an entrapment efficiency of 15.7 ± 0.2 
mg/cm2, similar to the 160:40 combination.  
As hypothesized, the maximum entrapment efficiency was achieved when 
microparticles’ size matched the micropillars spacing. From all the tested formulations, 
the 80:80 µm combination showed the highest entrapment efficiency and greatest filling 
of the PMP.  
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 Figure 4.3. Entrapping assays of PCL microparticles within PDMS micrpatterning patches (PMP), 
Graphical representation of the entrapment efficiency of microparticles with different diameters, namely 
A. 40 µm, B. 80 µm and C. 160 µm, entrapped within PMP with varying micropillars spacing (40, 80 
and 160 µm); D. Graphical representation of the entrapment efficiency of microparticles with 80 µm of 
diameter within PMP with 10:1 of flexibility and variable micropillars height, namely 100, 300 and 550 
µm. At the right side of the graphic are shown SEM images of such PMP with variable micropillars 
height but only for the 80:80 system (microparticles diameter:micropillars height); E. Graphical 
representation of the entrapment efficiency of microparticles with 80 µm of diameter within PMP with 
300 µm of micropillars height and variable flexibilities, namely 5:1, 10:1, and 15:1. At the right side of 
the graphic are shown SEM images of such PMP with variable flexibilities but only for the 80:80 system 
(microparticles diameter:micropillars height); P<0.1*, P<0.01**, P<0.001***, P<0.001****.  
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3.2.2. Micropillars height  
According to Figures 4.3A-C, an increased entrapment efficiency of 
microparticles was achieved for the intermediate micropillars height with 300 µm, while 
the lowest micropillars of 100 μm have demonstrated to generate the lowest entrapment 
efficiency. Therefore, different micropillars heights, namely 100, 300, and 550 m, with 
an intermediate mold flexibility of 10:1 were also tested with entrapped PCL 
microparticles with 80µm of diameter (Figure 4.3 D). At the right side of the graphic 
presenting the entrapment efficiency of such PMP, are depicted the respective SEM 
images of the three differently height PMP for the 80:80 µm system. As visualized by 
SEM, the lowest micropillars of 100 μm presented the lowest entrapment efficiency since 
such type of PMP was only able to entrap few layers of microparticles. This is explained 
by the fact that the diameter of PCL microparticles of 80 µm was similar to the 
micropillars height of 100 µm. In fact, for the 80:80 system, an increase of the entrapment 
efficiency from 18.3 ± 0.4 µm to 24.8 ± 0.4 µm (p<0.0001****) could be observed when 
an increment in micropillars height from 100 µm to 300 µm occurred. Additionally, again 
for the 80:80 system, when comparing the lowest height of 100 µm with the highest height 
of 550 µm a significant increase (p<0.01**) in microparticles entrapment could be 
observed for the late. Nevertheless, such result (20.6 ± 0.4 µm) is still significantly lower 
than the 300 µm height PMP (p<0.0001****). This can be explained by the existence of 
empty spaces along the vertical structures of such PMP system with 550µm of height, 
showed in SEM images.  
3.2.3. Patch flexibility  
Another important parameter is the flexibility of the PMP. Different flexibilities 
were obtained though the variation of PDMS base and curing agent ratios. For the 
purpose, three different base:curing agent ratios, namely 5:1, 10:1 and 15:1, were 
investigated for PMP entrapping 80 µm microparticles within micropillars height of 300 
µm (Figure 4.3E). SEM images of such PMP with different PMP flexibilities for the 
80:80 system are depicted on the right side of the graphic. For all flexibilities, the PMP 
were almost completely filled with entrapment efficiencies above 20 mg/cm2. Similarly, 
to bee’s body and foreleg hair, which are not rigid structures and bend to accommodate 
the maximum amount of grain pollens, some flexibility is also herein required to 
maximize the entrapment of microparticles. Results show that for the 80:80 system the 
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entrapment efficiency increased from 18.4 ± 2.3 (5:1) to 24.8 ± 0.4 mg/cm2 (10:1) 
(p<0.001***). However, the most flexible PMP herein developed (15:1) was not able to 
support and retain the highest amount of microparticles, and thus a small and non-
significant decrease (23.5 ± 0.6) when compared to 10:1 was verified. Overall, the results 
obtained demonstrate that PMP with both microparticles and micropillars spacing of 80 
µm (80:80) combined with an intermediate micropillars height (300 µm) and mold 
flexibility (10:1 PDMS ratio) are the most profitable system with an entrapment 
efficiency of 24.8 ± 0.4 mg/cm2. Therefore, such PMP was elected as an optimized 
hierarchal patch, and was further in vitro evaluated. 
We hypothesise that the flexibility of the membranes could allow for the release 
of entrapped microparticles by a simple stretching and shaking. We expect that the 
average spacing between micropillars will increase due to the increase of the strain, 
leading to a decrease of the mechanical locking effect of the microparticles. A simple 
qualitative experiment was performed where we could observe that a signification 
fraction of entrapped microparticles could be released by a simple hand stretching 
combined with a mild shaking of the membrane. The shaking alone basically maintained 
the microparticles that were kept mechanically locked within the micropillars. Even with 
the outflow of compressed air over the membranes, the microparticles were found to be 
fixed.  
 
3.3.Patches for drug delivery application 
In order to explore the applicability of our biomimetic surface obtained in the last 
section, patches were established to the fixation of solid microparticles for drug delivery 
applications. For the proof-of-concept, tetracycline hydrochloride was used as API to in 
vitro release studies and the determination of the antibacterial activity.  
3.3.1. Production of tetracycline-loaded alginate microparticles  
Alginate microparticles were obtained by electrospray technique. Different 
parameters of the system were tested, namely by varying the flow rate, working voltage, 
and needle diameter. A working voltage of 15kV and 26G needle were associated with 
non-spherical microparticles and higher polydispersity, while lower flow rates resulted in 
smaller microparticles. Monodisperse microparticles with approximately 80 µm and a 
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spherical shape were obtained when a flow rate of 1 mL/h was combined with a 22G 
needle and a working voltage of 15kV. Results are displayed in Figure 4.4.  
 
In the production of tetracycline-loaded alginate microparticles (TLM) two 
different approaches were tested. The first one consisted in previously mixing tetracycline 
and alginate solutions. However, drug addition to the alginate solution resulted in high 
polydispersity and larger microparticles with two distinct microparticles populations, 
namely between 60-100 µm and 250-350 µm. To overcome this limitation, different 
parameters for microparticles production (flow rate, voltage, needle diameter, collector 
distance, and tetracycline and alginate concentrations) were optimized to obtain the 
desired tetracycline-alginate microparticles diameter around 80 µm. The results showed 
that a flow rate of 1 mL/h, 15kV working voltage, 1.75 % (w/v) alginate concentration, 
2.5 mg/mL tetracycline concentration, 26G needle and distance-needle to the collector of 
6 cm yielded the spherical shape and small tetracycline-alginate microparticles with 
approximately 80 µm (Figure 4.4 C). The second approach consisted in the immersion 
of the previously produced non-loaded alginate microparticles on a concentrated 
tetracycline bath (2.5 mg/mL). The most efficient approach was determined through the 
calculations of drug content and encapsulation efficiencies. Higher values were obtained 
with the second methodology resulting in a drug content of 2.10 ± 0.09 % and an 
encapsulation efficiency of 22.7 ± 1.0 %. Although the first approach presented a similar 
encapsulation efficiency (20.2 ± 1.4%), the drug content dropped substantially to 1.27 ± 
0.14 %.  
Figure 4.4. Alginate microparticles obtained by electrospray technique and visualized by light microscopy. 
A. Non-loaded alginate microparticles of with 80 µm of diameter. Scale bar is 200 µm. Parameters: 1 m.L/h 
flow rate, 22 G needle, and a working voltage of 15 kV. B. Higher magnification of A. Scale bar is 80 µm. 
C. Tetracycline-powder alginate microparticles using 2.5 mg/mL of tetracycline hydrochloride. Scale bar 
is 200 µm. D. Non-loaded alginate microparticles. Parameters: 1.75 % (w/v) alginate, 26 G needle, flow 
rate (1 mL/h), 15kV working voltage, and distance to the collector of 6 cm.  
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3.3.2. In vitro release studies 
TLM and tetracycline powder (previously milled until the desired size of 80 µm) 
were entrapped in the PMP. Both constructs were incubated in PBS at pH 7.4 
(physiological) and pH 5.5 (wound). TLM alone (not coupled with PMP) were also 
incubated. The cumulative release profile of the encapsulated drug is depicted in Figure 
4.5A. As demonstrated, the total amount of tetracycline powder entrapped in PMP was 
released within 5 minutes for both pH.  
 
Figure 4.5. Antimicrobial activity and in vitro release assays from PDMS micrpatterning patches (PMP); 
Antimicrobial activity of the different combinations- PMP, PMP with non-loaded alginate microparticles, 
PMP with tetracycline-loaded alginate microparticles (TLM) and PMP with tetracycline powder against 
two microorganisms; A. In vitro cumulative release of tetracycline from PMP; B. Graphical representation 
of the inhibition zone (mm) of the different constructs; C. Disposition of the different combinations on 
plate; D. Antibiogram to Gram-negative Escherichia coli; E. Antibiogram to Gram-positive Staphylococus  
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A more controlled and sustained release of the drug was obtained through the 
encapsulation of tetracycline in alginate microparticles, enabling the engineering of a 
hierarchal patch with adequate features for drug delivery purposes. In fact, for each pH, 
the drug release from both systems TLM and TLM+PMP, is similar between them: 68.8 
± 2.1 and 71.1 ± 1.2, respectively for pH 5.5; and 79.3 ± 1.4 and 81.6 ± 3.8, respectively 
for pH 7.4 at the end of 5 days. An initial burst release is observed for these two 
formulations at both pH, where at least 50 % of the drug content is released within 
minutes.  
3.3.3. Antibacterial studies of the prepared dressings 
Growth inhibition assays for the different patches combinations (PMP with TMP 
and PMP with tetracycline powder) were performed against two common pathogens, in 
which tetracycline has demonstrated antibacterial activity - E. coli and S. aureus.[20] The 
different constructs were placed into the inoculation medium to inhibit the bacterial 
growth. PMP and PMP with alginate microparticles were used as controls. As expected, 
no inhibition zone was formed, demonstrating that such controls do not possess any 
inhibitory activity against the specific strains (Figure 4.5D and 4.5E). In contrast, both 
constructs with tetracycline showed antibacterial activity against the different bacterial 
strains. Nevertheless, it is discernible that there is a proportional relation between drug 
concentration and antibacterial activity. PMP with tetracycline powder showed an 
enhanced antimicrobial activity due the highest drug concentration (100 % w/w). 
Significant smaller inhibition zones (p<0.01**) were achieved, in both strains, for PMP 
with TLM where the drug content within the patch is only 2.10 ± 0.09 % (w/w).  
4. Discussion  
Hair spacing on bees’foreleg is proposed to dictate leg’s ability to store the 
microsized pollen during pollination.[7] Inspired by this extremely efficient system, where 
honey bees tune their body and foreleg hairs to accommodate a large amount of pollen 
grains, a new biomimetic structure for physically support the entrapment of 
microparticles was herein proposed. For this aim, a micropatterned structure able to 
mimic the bees’ leg hair was obtained through the fabrication of PMP with spaced 
micropillars. Results showed that such constructs were able to entrap a large amount of 
different microparticles. As hypothesized, the maximum entrapment efficiency was 
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achieved when the diameter of microparticles matched the micropillars spacing, 
regardless of PMP geometry arrangement. Particularly, the PMP formulation of 
80:80:300m (microparticle diameter:micropillar spacing:micropillar height) with 10:1 
flexibility, represent the most effective patch with an increased entrapment efficiency of 
24.8 ± 0.4 mg/cm2 against the 5 mg/cm2, usually detected in the current commercially 
available patches approved by the US Food and Drug Administration (FDA).[21] In the 
biological example of honey bees, an increased hair length represents a bigger volume 
available to accumulate grain pollens.[7] The results herein detailed demonstrated that a 
compromise between height and microparticles accumulation is established. Hence, the 
results herein exhibited demonstrate that an intermediate height of the micropillars, 
increases the patch entrapment efficiency. Similar trends were obtained for all differently 
spaced PMP. Furthermore, the developed PMP present a simple design and it is 
mechanically resistant, encouraging its applications in situations where stretching and 
bending is likely to occur.  
We also demonstrated that hydrogel microparticles could be immobilized in the 
developed bioinspired substrates, in order to demonstrate the adequacy of these systems 
to the used as patches for sustained drug release. Alginate has been widely used in 
hydrogels for biomedical applications, particularly in the encapsulation of a wide range 
of drugs, due to its low toxicity and cost.[22] TLM with an average size of 80m, were 
produced through electrospray, a suitable technique to engineer monodispersed drug-
loaded polymeric particles with diameters ranging from nano to micrometers,[23,24] with a 
drug loading of 2.10 ± 0.09 % and encapsulation efficiency of 22.7 ± 1.0 %. Martins and 
co-workers presented similar results with insulin-loaded alginate microparticles (1.78  
0.09 mm), achieving a maximum drug loading of 2.48 ± 0.01 % but higher encapsulation 
efficiency (80.0 ±0.8 %).[25] The authors justified the low loading capacity and 
encapsulation efficiency with the hydrophilic character of the drug and the large gel 
porosity, causing leakage of the loaded drugs and faster drug diffusion from the alginate 
to the crosslinking bath of calcium chloride. To overcome this limitation the alginate 
microparticles could be combined with other polymers. An example is the use of poli(3-
hidroxibutirato-co-3-hidroxivalerato) (PHBHV) in tretacycline-loaded alginate 
microparticles, known to increase the drug content to 5%.[26] 
Wound healing is normally divided in three steps: inflammation, proliferation and 
remodelling. Antibiotics, such as tetracycline, mainly act during the inflammatory phase, 
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which lasts for about 5 days.[27,28] The incorporation of drug carries (TLM) in the PMP 
allowed a more controlled and sustained release of the API for 5 days, when compared to 
the tetracycline powder-PMP system, where an immediate drug release was observed. 
The burst release can be easily explained by the probable superficial adsorption of 
tetracycline in the alginate microparticles. Due to the methodology herein described for 
drug encapsulation, it is extremely likely that the API has remained on the outermost of 
the particles, entrapped in their crosslinked network. Also, tetracycline’s low molecular 
weight (444.435 g.mol-1) may accentuate the concentration gradient, increasing osmotic 
pressure and causing such burst effect.[29] As result, when microparticles are placed in 
contact with an aqueous medium, a rapid diffusion is expected to occur. Additionally, at 
pH 5.5, the carboxylic acid group from alginate can be partially deprotonated (pKa  3.2), 
which leads to a faster polymer dissolution, and consequently increasing such initial 
release. Nevertheless, after 4h, the osmotic pressure appears to be overcome for pH 5.5, 
probably due to alginate deterioration, and a steady state is achieved. Nevertheless, at pH 
7.4, where the majority of microparticles are still intact, such osmotic pressure continues 
to play an active role, and a sustained release of the drug can still be observed.  
Burst events followed by a controlled and sustained release of drug are of 
particular interest in wounds treatment, where an initial burst provides immediate relief 
followed by prolonged release to promote gradual healing.[29] Thereupon, these findings 
demonstrate that the PMP herein developed could be perfectly applied either in wound 
healing situations or other events that require topical transdermal delivery of a drug. 
Nevertheless, both constructs have manifested remarkable antimicrobial activity against 
gram-negative and gram-positive bacteria.  
The results herein obtained suggest that such optimized and hierarchal system 
could be further considered for the development of bioinspired devices that provide the 
entrapment of huge amount of different microparticles. The fabrication of hairy substrates 
could be extended to other materials (including biodegradable polymers) and non-flat 
geometries. As reported in this work, an optimized patch could be developed for clinical 
applications, able to fix high quantity of drug powder or microparticles encapsulating 
drugs. Such entrapment could be easily done by a simple contact of the patch with any 
powdery product formulated from the shelf. This could be a valuable solution for the 
treatment of diseases that require high-drug concentration, enabling less frequent dosing, 
and thus significantly improving patient compliance. We hypothesize that this system 
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could be applied as a platform to the development of a wide variety of micropatterned 
structures with different applicability in, for example, biomedical, biotech and industrial 
fields. 
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Figure S1. Graphical representation of the entrapment efficiency of. microparticles’ trapping assays. A. 
microparticles with 40 µm of diameter within PMP with 5:1 of flexibility; B. microparticles with 40 µm of 
diameter within PMP with 15:1 of flexibility; C. microparticles with 80 µm of diameter within PMP with 
5:1 of flexibility; D. microparticles with 80 µm of diameter within PMP with 15:1 of flexibility; E. 
microparticles with 160 µm of diameter within PMP with 5:1 of flexibility; F. microparticles with 160 µm 
of diameter within PMP with 15:1 of flexibility. 
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Figure S2. SEM images of negative and positive PMP with both geometries (square and hexagonal). 
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Figure S3. PCL microparticles obtained by emulsion technique; A. SEM images of PCL microparticles 
before sieving; B. SEM images of PCL microparticles after sieving; C. Microparticle size distribution of 
PCL microparticles produced by emulsion technique.  
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Figure S5. SEM images of PMP with microparticles diameters superior to micropillars spacing; A. 80 µm 
microparticles with 40 µm micropillars spacing. Magnification 100x; B. 160 µm microparticles with 80 µm 
micropillars spacing. Magnification 100x; C. 160 µm microparticles with 40 µm micropillars spacing. 
Magnification 100x; D. 80 µm microparticles with 40 µm micropillars spacing. Magnification 600x; E. 160 
µm microparticles with 80 µm micropillars spacing. Magnification 600x; F. 160 µm microparticles with 
40 µm micropillars spacing. Magnification 600x 
Figure S4. SEM images of PMP with microparticles diameters inferior to micropillars spacing; A. 40 µm 
microparticles with 80 µm micropillars spacing. Magnification 100x; B. 40 µm microparticles with 160 µm 
micropillars spacing. Magnification 100x; C. 80 µm microparticles with 160 µm micropillars spacing. 
Magnification 100x; D. 40 µm microparticles with 80 µm micropillars spacing. Magnification 600x; E. 40 
µm microparticles with 160 µm micropillars spacing. Magnification 600x; F. 40 µm microparticles with 
160 µm micropillars spacing. Magnification 600x. 
CHAPTER 4  PHYSICAL SUPPORTS FOR THE IMMOBILIZATION OF PARTICLES INSPIRED BY POLLINATION 
 
81 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
Figure S6. SEM images of PMP with microparticles diameters similar to micropillars spacing; A. 40 µm 
microparticles with 40 µm micropillars spacing. Magnification 100x; B. 80 µm microparticles with 80 µm 
micropillars spacing. Magnification 100x; C. 160 µm microparticles with 160 µm micropillars. 
Magnification 100x spacing; D. 40 µm microparticles with 40 µm micropillars spacing. Magnification 
600x; E. 80 µm microparticles with 80 µm micropillars spacing. Magnification 600x; F. 160 µm 
microparticles with 160 µm micropillars. Magnification 100x spacing. 
Figure S7. SEM images of PMP with PCL microparticles entrapped between the micropillars. 
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Figure S8. Fluorescence microscopy of PMP with 40 µm fluorescent PCL microparticles and with 
different micropillars spacing: A. 40 µm. Magnification 5x; B. 80 µm. Magnification 5x; C. 160 µm.. 
Magnification 5x; D. 40 µm. Magnification 10x; E. 80 µm. Magnification 10x; and F. 160 µm.. 
Magnification 10x. 
Figure S9. Fluorescence microscopy of PMP with 80 µm fluorescent PCL microparticles and with different 
micropillars spacing: A. 40 µm. Magnification 5x; B. 80 µm. Magnification 5x; C. 160 µm.. Magnification 
5x; D. 40 µm. Magnification 10x; E. 80 µm. Magnification 10x; and F. 160 µm.. Magnification 10x. 
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Table S2. Production of alginate microparticles by electrospray. Different parameters were tested using 
alginate solution 2% (w/v), diameter tube of 0.5 mm and distance to the collector. of 6 cm. 
 
 
Flow rate 
(mL/h) 
Voltage 
(kV) 
Needle Shape Size 
10 10 26G 
2 populations 
(spherical) 
± 200 µm 
± 110 µm 
5 
10 26G Spherical 
> 120 µm with 
polydispersity 
15 26G Shapeless - 
1 
15 26G Shapeless 
Very large and high 
polydispersity 
15 22G Spherical 80-90 µm 
Figure S10. Fluorescence microscopy of PMP with 160 µm fluorescent PCL microparticles and with 
different micropillars spacing: A. 40 µm. Magnification 5x; B. 80 µm. Magnification 5x; C. 160 µm.. 
Magnification 5x; D. 40 µm. Magnification 10x; E. 80 µm. Magnification 10x; and F. 160 µm.. 
Magnification 10x. 
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Chapter 5- Final Overview, concluding remarks and future 
prospects 
The development of novel and pioneering therapeutic devices is emerging nowadays 
and one of the major goal includes the development of new and optimized drug delivery 
systems (DDS) capable of enhancing conventional treatments efficacy and/or to avoid the 
commonly associated side effects. 
CHAPTER 1 encompasses the thesis motivation combined with the wound healing 
concerns and with the advantages that can arise from the development of a bioinspired 
optimized transdermal DDS. Inspired by animals such as insects, many biomimetic synthetic 
adhesives have been studied in order to support macroscopic masses. Honey bees, for 
instance, have a typical branched hair and pollen grains are caught and held between the 
barbs of adjacent hair.  In pollination, the hairy covering the body allows the temporary 
retention of pollen, followed by removal through the combined action of legs' brushes. An 
optimized bioinspired system can, therefore, be developed based on the pollination process 
though the adhesion between particles and micro-patterned soft matter surfaces.  
Transdermal drug delivery has been investigated as a successful drug delivery 
platform. Due to their simple design, application and low production cost, patches still the 
most commonly transdermal DDS present in the market. In order to recognize their benefits 
and limitations, CHAPTER 2 makes a review that highlights the efforts developed in last 
years regarding the production of patches with different designs and their potential 
application in drug delivery. Current commercially available transdermal patches and 
clinical trials are also included. Although major achievements have been attained in the 
development of more sophisticated patches, some limitations still need to be overcome. In 
fact, drug' physicochemical properties continue to play an important role in its transport 
through the skin layers. Consequently, low transcutaneous flux, drug incorporation and 
retention in the patch still restraint their application.  
The work detailed in this thesis reveals the extraordinary advantages of combining 
the biomimetic concept with microfabrication techniques to develop a robust bioinspired 
hierarchal patch based on the extraordinary and organized bee’s ability to catch and release 
the pollen during pollination in order to overcome the current patches limitations. The major 
goals of the present thesis were: i) the development of a new design of a micropatterned 
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patch with micropillars (that mimics bees' legs) to catch a certain amount of drug; ii) the 
engineering of a novel and optimized system for transdermal drug delivery purposes iii) to 
support the hypothesis that grains pollen are catch between hair legs because this distance is 
equal to grains pollen sizes and define the most effective system. For this purpose, different 
conjugations of a system composed of a PDMS micropatterning patch together with 
differently sized drug microparticles were investigated to act in a controlled and sustained 
manner during the inflammatory phase of a wound.  
CHAPTER 3 thoroughly described the materials and methods and also presents the 
results and discussion of preliminary steps performed during the development of the work.  
With the goal of designing an optimized patch, in CHAPTER 4 a robust bioinspired 
patch with simple design was successful engineering based on pollination process. A PDMS 
micropatterning patch with micropillars was obtained by casting process. Differently sized 
PCL microparticles (obtained by emulsion technique) were combined with different PDMS 
micropatterning patch to achieve the most effective system. The patch filling with 
microparticles was accessed by SEM and fluorescence microscopy. The hypothesis previous 
described was supported. An optimized system was achieved through the perfect 
combination of microparticles' diameters and micropillars distance from the patch to 
controlled and sustained release of the drug. In fact, an entrapment efficiency of 24.8 ± 0.4 
mg·cm-2 was achieved with a size patch of 1.44 cm2, improving to a great extend the 
commercially available patches. According to Table 2.3 (CHAPTER 2), the current patch 
drugs approved by FDA in the market present a dose much lower than system proposed, less 
than 5.1 mg·cm-2 (36 mg in 7 cm2). It is foreseen that the proposed hierarchal patches will 
be a valuable solution for the treatment of diseases that require high-drug concentration 
enabling less frequent dosing, therefore improving patient compliance. 
The release profile was determinate for two different systems: patches with both 
tetracycline powder microparticles and tetracycline-loaded alginate microparticles, a model 
antibiotic, expected to act during the inflammatory phase of the wound healing process. 
While tetracycline powder was immediately release, the other ones allowed a controlled 
release for 5 days. Drug carriers (tetracycline-loaded alginate microparticles) allowed a more 
sustained drug release when compared to tetracycline powder. The hierarchical patch 
activity was verified through antimicrobial assays, proving their antimicrobial action against 
both gram-negative and gram-positive bacteria. Still, this patch is not limitative, being a 
CHAPTER 5  FINAL OVERVIEW, CONCLUDING REMARKS AND FUTURE PROSPECTS 
 
86 
 
platform that can be applied to a large pool of drugs and that can be coupled with other 
techniques to develop a wide variety of patches.  
Ultimately, the investigation conducted in this thesis and the findings that resulted 
from it enabled the successful development of potential bioinspired patch for clinical 
applications. The goals of this thesis were successfully achieved and bring new insights that 
could solve the current problems associated with passive drug delivery patches. 
Although the work herein detailed may present huge advances in biomimetic systems 
for transdermal drug delivery and patches designs, more efforts need to be performed to 
translate these approaches into clinical applications. In vivo contributions regarding the use 
of PDMS micropattermig patch must be addressed in order to convince the pharmaceutical 
industries to adopt such strategy. Accurate pharmacokinetics and pharmacodynamics 
studies, (meaning what happens to the drug microparticles after their deposition in the skin 
and what are the effects of such particles/biomolecules in the body, respectively) need to be 
fully investigated to assure clinical relevance. Moreover, biocompatible and biodegradable 
polymers, mostly natural ones have been received careful attention due to their 
biocompatibility, low toxicity and susceptibility to degradation by human enzymes. 
Alternatives to PDMS must be debated.  
Forthcoming works that can arise from this thesis and be implemented in a near future 
include:  
. i) Replacement of PDMS patches engineered in CHAPTER 4 by natural and/or 
biodegradable polymers. 
. ii) In vivo assays - determination of transcutaneous flux, plasma level and biocompatibility 
assays. 
 
 
